_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,direction,b1,b2,direction_gold,e1,e2,relation,relex_relcos,sent_id,sentence,term1,term2,twrex
503223341,7/15/2014 10:26:02,,1323486534,7/15/2014 10:25:36,rewardsspot,0.8889,24482174,GBR,H9,London,46.23.68.180,PREGNANCY contraindicates CAPTOPRIL,41,6,,49,15,contraindicates,0.970725343394151,901494-FS1-10,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY,RO-contraindicated_drug
503223341,7/15/2014 10:52:42,,1323504934,7/15/2014 10:52:15,rewardsspot,0.6319,17763704,USA,VA,Manassas,198.7.62.204,CAPTOPRIL contraindicates PREGNANCY,41,6,,49,15,contraindicates,0.970725343394151,901494-FS1-10,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY,RO-contraindicated_drug
503223341,7/15/2014 11:03:55,,1323511882,7/15/2014 11:03:34,prodege,0.6528,28039757,GBR,L8,Southport,109.155.158.54,no_relation,41,6,,49,15,contraindicates,0.970725343394151,901494-FS1-10,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY,RO-contraindicated_drug
503223341,7/15/2014 11:11:43,,1323518563,7/15/2014 11:11:05,elite,0.7417,28397222,GBR,Y4,Usk,31.50.223.75,PREGNANCY contraindicates CAPTOPRIL,41,6,,49,15,contraindicates,0.970725343394151,901494-FS1-10,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY,RO-contraindicated_drug
503223341,7/15/2014 11:12:25,,1323519099,7/15/2014 11:11:59,prodege,0.7681,11864493,GBR,Z4,Wrexham,212.219.196.69,no_relation,41,6,,49,15,contraindicates,0.970725343394151,901494-FS1-10,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY,RO-contraindicated_drug
503223341,7/15/2014 11:48:29,,1323540105,7/15/2014 11:48:15,neodev,0.6637,21515166,NLD,11,Nootdorp,83.86.58.179,CAPTOPRIL contraindicates PREGNANCY,41,6,,49,15,contraindicates,0.970725343394151,901494-FS1-10,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY,RO-contraindicated_drug
503223341,7/15/2014 13:50:10,,1323586788,7/15/2014 13:49:47,prodege,0.6706,13795372,CAN,NS,Dartmouth,142.68.155.182,no_relation,41,6,,49,15,contraindicates,0.970725343394151,901494-FS1-10,"?  If PREGNANCY is detected, discontinue CAPTOPRIL as soon as possible.",CAPTOPRIL,PREGNANCY,RO-contraindicated_drug
503223342,7/15/2014 11:51:46,,1323542305,7/15/2014 11:51:12,neodev,0.6736,24578640,USA,IL,Chicago,65.60.20.66,TRICHOFOLLICULOMA contraindicates FOLLICULAR DIFFERENTIATION,87,171,,112,188,contraindicates,0.4,901731-FS1-10,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223342,7/15/2014 12:39:57,,1323561739,7/15/2014 12:39:41,instagc,0.7472,18960682,GBR,"","",86.29.147.112,FOLLICULAR DIFFERENTIATION contraindicates TRICHOFOLLICULOMA,87,171,,112,188,contraindicates,0.4,901731-FS1-10,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223342,7/15/2014 13:47:28,,1323586075,7/15/2014 13:46:56,prodege,0.6706,13795372,CAN,NS,Dartmouth,142.68.155.182,FOLLICULAR DIFFERENTIATION contraindicates TRICHOFOLLICULOMA,87,171,,112,188,contraindicates,0.4,901731-FS1-10,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223342,7/15/2014 14:29:03,,1323597929,7/15/2014 14:28:47,elite,0.6381,28276268,USA,FL,Boynton Beach,99.114.225.45,FOLLICULAR DIFFERENTIATION contraindicates TRICHOFOLLICULOMA,87,171,,112,188,contraindicates,0.4,901731-FS1-10,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223342,7/15/2014 14:32:41,,1323599028,7/15/2014 14:32:36,neodev,0.3913,25224036,CAN,ON,Sudbury,67.204.218.187,FOLLICULAR DIFFERENTIATION contraindicates TRICHOFOLLICULOMA,87,171,,112,188,contraindicates,0.4,901731-FS1-10,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223342,7/15/2014 16:25:16,,1323671678,7/15/2014 16:25:03,clixsense,0.475,16827630,GBR,A7,Birmingham,86.146.169.103,FOLLICULAR DIFFERENTIATION contraindicates TRICHOFOLLICULOMA,87,171,,112,188,contraindicates,0.4,901731-FS1-10,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223342,7/15/2014 16:45:38,,1323696032,7/15/2014 16:45:30,prodege,0.474,2143114,CAN,BC,Vancouver,24.84.160.12,TRICHOFOLLICULOMA contraindicates FOLLICULAR DIFFERENTIATION,87,171,,112,188,contraindicates,0.4,901731-FS1-10,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223343,7/15/2014 10:08:30,,1323475778,7/15/2014 10:08:04,clixsense,0.875,15189335,GBR,E4,Colchester,5.67.141.89,IBUPROFEN treats INFLAMMATION,103,36,,114,45,treats,1,908220-FS1-2,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN,RO-may_treat
503223343,7/15/2014 10:50:57,,1323503710,7/15/2014 10:50:01,rewardsspot,0.6319,17763704,USA,VA,Manassas,198.7.62.204,IBUPROFEN treats INFLAMMATION,103,36,,114,45,treats,1,908220-FS1-2,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN,RO-may_treat
503223343,7/15/2014 11:20:24,,1323524118,7/15/2014 11:20:07,instagc,0.8431,13763729,USA,"","",75.182.89.225,IBUPROFEN treats INFLAMMATION,103,36,,114,45,treats,1,908220-FS1-2,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN,RO-may_treat
503223343,7/15/2014 11:25:30,,1323526893,7/15/2014 11:25:19,prodege,0.7792,15439740,AUS,02,Jannali,27.96.208.89,IBUPROFEN treats INFLAMMATION,103,36,,114,45,treats,1,908220-FS1-2,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN,RO-may_treat
503223343,7/15/2014 11:52:57,,1323543265,7/15/2014 11:52:34,neodev,0.6736,24578640,USA,IL,Chicago,65.60.20.66,IBUPROFEN treats INFLAMMATION,103,36,,114,45,treats,1,908220-FS1-2,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN,RO-may_treat
503223343,7/15/2014 12:58:18,,1323568971,7/15/2014 12:58:00,elite,0.8028,28503042,USA,NJ,Woodbridge,54.191.150.115,IBUPROFEN treats INFLAMMATION,103,36,,114,45,treats,1,908220-FS1-2,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN,RO-may_treat
503223343,7/15/2014 15:22:43,,1323621370,7/15/2014 15:22:07,prodege,0.5683,7899370,USA,MI,Bay City,71.13.81.162,IBUPROFEN treats INFLAMMATION,103,36,,114,45,treats,1,908220-FS1-2,"The evidence for modes of action of IBUPROFEN are considered in relation to its actions in controlling INFLAMMATION pain and fever, as well as the adverse effects of the drug.",INFLAMMATION,IBUPROFEN,RO-may_treat
503223344,7/15/2014 10:20:29,,1323483164,7/15/2014 10:19:56,gifthulk,0.9583,22144176,GBR,U8,Edinburgh,129.215.149.99,LUNG is location of LUNG CANCER,162,233,,165,244,is location of,0.973328526784575,905225-FS1-9,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER,RO-has_finding_site
503223344,7/15/2014 10:51:23,,1323504071,7/15/2014 10:51:12,clixsense,0.8486,27793793,GBR,C5,Chester,151.230.27.155,LUNG is location of LUNG CANCER,162,233,,165,244,is location of,0.973328526784575,905225-FS1-9,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER,RO-has_finding_site
503223344,7/15/2014 11:25:30,,1323526906,7/15/2014 11:25:19,prodege,0.7792,15439740,AUS,02,Jannali,27.96.208.89,LUNG is location of LUNG CANCER,162,233,,165,244,is location of,0.973328526784575,905225-FS1-9,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER,RO-has_finding_site
503223344,7/15/2014 13:05:16,,1323571745,7/15/2014 13:05:04,clixsense,0.601,20614047,USA,ID,Priest River,174.32.160.124,LUNG is location of LUNG CANCER,162,233,,165,244,is location of,0.973328526784575,905225-FS1-9,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER,RO-has_finding_site
503223344,7/15/2014 14:10:54,,1323592695,7/15/2014 14:10:33,neodev,0.4365,28336203,USA,PA,Harrisburg,50.149.53.150,LUNG CANCER is location of LUNG,162,233,,165,244,is location of,0.973328526784575,905225-FS1-9,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER,RO-has_finding_site
503223344,7/15/2014 14:20:38,,1323595417,7/15/2014 14:20:13,instagc,0.6554,19636746,USA,NY,Andover,192.182.216.225,LUNG is location of LUNG CANCER,162,233,,165,244,is location of,0.973328526784575,905225-FS1-9,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER,RO-has_finding_site
503223344,7/15/2014 15:30:42,,1323626965,7/15/2014 15:30:24,tremorgames,0.5508,24449707,CAN,QC,Laval,96.21.249.72,LUNG is location of LUNG CANCER,162,233,,165,244,is location of,0.973328526784575,905225-FS1-9,"The frequencies of abnormal transcripts were 59% in lung cancer, 35% in paired normal lung, and 64% in normal control lung; the difference in frequencies between LUNG cancer and paired normal lung was significant, while that between LUNG CANCER and normal control lung was not.",LUNG,LUNG CANCER,RO-has_finding_site
503223345,7/15/2014 10:07:27,,1323475170,7/15/2014 10:06:51,clixsense,0.875,15189335,GBR,E4,Colchester,5.67.141.89,no_relation,67,34,,108,55,treats,0.943879807448539,900136-FS1-2,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,RO-cause_of
503223345,7/15/2014 10:18:50,,1323482000,7/15/2014 10:18:33,gifthulk,0.9583,22144176,GBR,U8,Edinburgh,129.215.149.99,no_relation,67,34,,108,55,treats,0.943879807448539,900136-FS1-2,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,RO-cause_of
503223345,7/15/2014 11:20:30,,1323524195,7/15/2014 11:20:05,instagc,0.7264,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,67,34,,108,55,treats,0.943879807448539,900136-FS1-2,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,RO-cause_of
503223345,7/15/2014 11:24:26,,1323526346,7/15/2014 11:23:38,prodege,0.7792,15439740,AUS,02,Jannali,27.96.208.89,no_relation,67,34,,108,55,treats,0.943879807448539,900136-FS1-2,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,RO-cause_of
503223345,7/15/2014 12:36:38,,1323560471,7/15/2014 12:36:06,prodege,0.5236,1852770,USA,TX,Abilene,76.198.102.54,HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA treats DIABETIC KETOACIDOSIS,67,34,,108,55,treats,0.943879807448539,900136-FS1-2,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,RO-cause_of
503223345,7/15/2014 13:53:05,,1323587621,7/15/2014 13:52:42,neodev,0.4671,18339121,USA,SC,Sumter,173.93.188.194,DIABETIC KETOACIDOSIS treats HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,67,34,,108,55,treats,0.943879807448539,900136-FS1-2,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,RO-cause_of
503223345,7/15/2014 14:12:11,,1323592979,7/15/2014 14:11:34,neodev,0.4365,28336203,USA,PA,Harrisburg,50.149.53.150,HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA treats DIABETIC KETOACIDOSIS,67,34,,108,55,treats,0.943879807448539,900136-FS1-2,"Diabetic ketoacidosis: diagnosis, DIABETIC KETOACIDOSIS treatment, HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA and maintenance treatment after hyperglycemic crisis.",HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,RO-cause_of
503223346,7/15/2014 10:07:49,,1323475424,7/15/2014 10:07:22,eup_slw,0.9167,20818028,GBR,A7,Birmingham,92.232.139.254,no_relation,61,0,,64,10,causes,0.348742916231458,905059-FS1-4,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS,RO-has_finding_site
503223346,7/15/2014 10:51:09,,1323503865,7/15/2014 10:50:57,clixsense,0.8486,27793793,GBR,C5,Chester,151.230.27.155,SKIN causes DERMATITIS,61,0,,64,10,causes,0.348742916231458,905059-FS1-4,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS,RO-has_finding_site
503223346,7/15/2014 11:04:44,,1323512622,7/15/2014 11:04:23,prodege,0.6528,28039757,GBR,L8,Southport,109.155.158.54,no_relation,61,0,,64,10,causes,0.348742916231458,905059-FS1-4,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS,RO-has_finding_site
503223346,7/15/2014 11:11:58,,1323518754,7/15/2014 11:11:17,prodege,0.7681,11864493,GBR,Z4,Wrexham,212.219.196.69,no_relation,61,0,,64,10,causes,0.348742916231458,905059-FS1-4,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS,RO-has_finding_site
503223346,7/15/2014 12:37:39,,1323560884,7/15/2014 12:37:00,prodege,0.5236,1852770,USA,TX,Abilene,76.198.102.54,no_relation,61,0,,64,10,causes,0.348742916231458,905059-FS1-4,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS,RO-has_finding_site
503223346,7/15/2014 12:39:07,,1323561454,7/15/2014 12:38:53,instagc,0.7472,18960682,GBR,"","",86.29.147.112,no_relation,61,0,,64,10,causes,0.348742916231458,905059-FS1-4,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS,RO-has_finding_site
503223346,7/15/2014 13:31:01,,1323580608,7/15/2014 13:30:41,instagc,0.5063,23149109,USA,NC,Cary,24.206.38.18,no_relation,61,0,,64,10,causes,0.348742916231458,905059-FS1-4,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS,RO-has_finding_site
503223347,7/15/2014 10:27:43,,1323487656,7/15/2014 10:27:07,vivatic,0.8056,25451531,GBR,"","",83.67.28.193,FACTOR VIII treats VON WILLEBRAND DISEASE,81,40,,102,51,treats,1,907758-FS1-2,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII,RO-may_treat
503223347,7/15/2014 10:28:36,,1323488331,7/15/2014 10:28:14,clixsense,0.8472,19803139,NLD,06,Veldhoven,212.61.84.196,FACTOR VIII treats VON WILLEBRAND DISEASE,81,40,,102,51,treats,1,907758-FS1-2,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII,RO-may_treat
503223347,7/15/2014 10:51:09,,1323503857,7/15/2014 10:50:57,clixsense,0.8486,27793793,GBR,C5,Chester,151.230.27.155,FACTOR VIII treats VON WILLEBRAND DISEASE,81,40,,102,51,treats,1,907758-FS1-2,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII,RO-may_treat
503223347,7/15/2014 11:27:06,,1323527770,7/15/2014 11:26:53,instagc,0.7611,28301350,GBR,K4,Plymouth,92.28.215.248,FACTOR VIII treats VON WILLEBRAND DISEASE,81,40,,102,51,treats,1,907758-FS1-2,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII,RO-may_treat
503223347,7/15/2014 11:37:55,,1323534065,7/15/2014 11:37:25,clixsense,0.5726,23233834,GBR,N6,Sunderland,86.17.58.181,FACTOR VIII treats VON WILLEBRAND DISEASE,81,40,,102,51,treats,1,907758-FS1-2,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII,RO-may_treat
503223347,7/15/2014 11:50:11,,1323541169,7/15/2014 11:49:45,neodev,0.6637,21515166,NLD,11,Nootdorp,83.86.58.179,FACTOR VIII treats VON WILLEBRAND DISEASE,81,40,,102,51,treats,1,907758-FS1-2,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII,RO-may_treat
503223347,7/15/2014 12:58:53,,1323569289,7/15/2014 12:58:40,elite,0.8028,28503042,USA,NJ,Woodbridge,54.191.150.115,FACTOR VIII treats VON WILLEBRAND DISEASE,81,40,,102,51,treats,1,907758-FS1-2,The use of intermediate and high purity FACTOR VIII products in the treatment of VON WILLEBRAND DISEASE.,VON WILLEBRAND DISEASE,FACTOR VIII,RO-may_treat
503223348,7/15/2014 10:29:09,,1323488646,7/15/2014 10:28:26,vivatic,0.8056,25451531,GBR,"","",83.67.28.193,THE TREATMENT OF VULVODYNIA FOUND THAT 17 causes ROBUST REDUCTION IN PAIN,124,49,,147,90,causes,0.424264068711929,904958-FS1-4,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17,RO-has_definitional_manifestation
503223348,7/15/2014 10:30:58,,1323489844,7/15/2014 10:30:50,clixsense,0.6875,19162475,GBR,M3,Frome,82.33.126.30,ROBUST REDUCTION IN PAIN causes THE TREATMENT OF VULVODYNIA FOUND THAT 17,124,49,,147,90,causes,0.424264068711929,904958-FS1-4,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17,RO-has_definitional_manifestation
503223348,7/15/2014 11:15:18,,1323520845,7/15/2014 11:15:03,clixsense,0.8306,27871219,NLD,07,Amsterdam,87.210.207.223,THE TREATMENT OF VULVODYNIA FOUND THAT 17 causes ROBUST REDUCTION IN PAIN,124,49,,147,90,causes,0.424264068711929,904958-FS1-4,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17,RO-has_definitional_manifestation
503223348,7/15/2014 11:18:32,,1323523008,7/15/2014 11:18:02,instagc,0.7264,24252915,GBR,B7,Bristol,77.98.139.82,THE TREATMENT OF VULVODYNIA FOUND THAT 17 causes ROBUST REDUCTION IN PAIN,124,49,,147,90,causes,0.424264068711929,904958-FS1-4,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17,RO-has_definitional_manifestation
503223348,7/15/2014 11:20:24,,1323524124,7/15/2014 11:20:07,instagc,0.8431,13763729,USA,"","",75.182.89.225,no_relation,124,49,,147,90,causes,0.424264068711929,904958-FS1-4,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17,RO-has_definitional_manifestation
503223348,7/15/2014 11:27:54,,1323528271,7/15/2014 11:27:20,elite,0.7417,28397222,GBR,Y4,Usk,31.50.223.75,no_relation,124,49,,147,90,causes,0.424264068711929,904958-FS1-4,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17,RO-has_definitional_manifestation
503223348,7/15/2014 11:38:25,,1323534406,7/15/2014 11:37:56,clixsense,0.5726,23233834,GBR,N6,Sunderland,86.17.58.181,THE TREATMENT OF VULVODYNIA FOUND THAT 17 causes ROBUST REDUCTION IN PAIN,124,49,,147,90,causes,0.424264068711929,904958-FS1-4,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17,RO-has_definitional_manifestation
503223349,7/15/2014 11:04:22,,1323512191,7/15/2014 11:03:56,prodege,0.6528,28039757,GBR,L8,Southport,109.155.158.54,no_relation,78,135,,104,146,treats,0.753778361444409,907406-FS1-2,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS,RO-may_prevent
503223349,7/15/2014 11:26:31,,1323527404,7/15/2014 11:26:15,instagc,0.7611,28301350,GBR,K4,Plymouth,92.28.215.248,ANTIEMETICS treats INDUCED NAUSEA AND VOMITING,78,135,,104,146,treats,0.753778361444409,907406-FS1-2,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS,RO-may_prevent
503223349,7/15/2014 11:51:46,,1323542308,7/15/2014 11:51:12,neodev,0.6736,24578640,USA,IL,Chicago,65.60.20.66,INDUCED NAUSEA AND VOMITING treats ANTIEMETICS,78,135,,104,146,treats,0.753778361444409,907406-FS1-2,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS,RO-may_prevent
503223349,7/15/2014 12:38:45,,1323561278,7/15/2014 12:38:12,prodege,0.5236,1852770,USA,TX,Abilene,76.198.102.54,no_relation,78,135,,104,146,treats,0.753778361444409,907406-FS1-2,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS,RO-may_prevent
503223349,7/15/2014 12:39:40,,1323561668,7/15/2014 12:39:23,instagc,0.7472,18960682,GBR,"","",86.29.147.112,INDUCED NAUSEA AND VOMITING treats ANTIEMETICS,78,135,,104,146,treats,0.753778361444409,907406-FS1-2,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS,RO-may_prevent
503223349,7/15/2014 13:04:24,,1323571485,7/15/2014 13:04:16,clixsense,0.601,20614047,USA,ID,Priest River,174.32.160.124,no_relation,78,135,,104,146,treats,0.753778361444409,907406-FS1-2,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS,RO-may_prevent
503223349,7/15/2014 13:11:59,,1323574241,7/15/2014 13:11:44,neodev,0.4365,28336203,USA,PA,Harrisburg,50.149.53.150,ANTIEMETICS treats INDUCED NAUSEA AND VOMITING,78,135,,104,146,treats,0.753778361444409,907406-FS1-2,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS,RO-may_prevent
503223350,7/15/2014 11:11:04,,1323518052,7/15/2014 11:10:08,elite,0.7417,28397222,GBR,Y4,Usk,31.50.223.75,DIABETES causes DIABETIC NEUROPATHY,105,44,,123,52,causes,0.977355554850442,900157-FS1-4,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES,RO-cause_of
503223350,7/15/2014 11:20:30,,1323524211,7/15/2014 11:20:05,instagc,0.7264,24252915,GBR,B7,Bristol,77.98.139.82,DIABETIC NEUROPATHY causes DIABETES,105,44,,123,52,causes,0.977355554850442,900157-FS1-4,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES,RO-cause_of
503223350,7/15/2014 12:23:52,,1323555752,7/15/2014 12:23:23,paiddailysurveys,0.6127,11786001,USA,NC,Charlotte,71.28.89.238,DIABETES causes DIABETIC NEUROPATHY,105,44,,123,52,causes,0.977355554850442,900157-FS1-4,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES,RO-cause_of
503223350,7/15/2014 12:36:57,,1323560598,7/15/2014 12:36:40,prodege,0.5236,1852770,USA,TX,Abilene,76.198.102.54,DIABETES causes DIABETIC NEUROPATHY,105,44,,123,52,causes,0.977355554850442,900157-FS1-4,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES,RO-cause_of
503223350,7/15/2014 13:30:01,,1323580301,7/15/2014 13:29:39,instagc,0.5063,23149109,USA,NC,Cary,24.206.38.18,DIABETIC NEUROPATHY causes DIABETES,105,44,,123,52,causes,0.977355554850442,900157-FS1-4,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES,RO-cause_of
503223350,7/15/2014 14:32:56,,1323599145,7/15/2014 14:32:50,neodev,0.3913,25224036,CAN,ON,Sudbury,67.204.218.187,DIABETIC NEUROPATHY causes DIABETES,105,44,,123,52,causes,0.977355554850442,900157-FS1-4,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES,RO-cause_of
503223350,7/15/2014 15:53:15,,1323643735,7/15/2014 15:53:01,neodev,0.624,14861092,GBR,I2,Manchester,90.194.137.76,DIABETES causes DIABETIC NEUROPATHY,105,44,,123,52,causes,0.977355554850442,900157-FS1-4,"The physician should ask about a history of DIABETES of long duration, including other manifestations of DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES,RO-cause_of
503223351,7/15/2014 14:27:43,,1323597538,7/15/2014 14:27:23,elite,0.6381,28276268,USA,FL,Boynton Beach,99.114.225.45,COLONIC ISCHEMIA causes SPONTANEOUS ISCHEMIC COLITIS,88,64,,115,80,causes,0.304997140665209,900053-FS1-4,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA,RO-cause_of
503223351,7/15/2014 14:32:56,,1323599146,7/15/2014 14:32:50,neodev,0.3913,25224036,CAN,ON,Sudbury,67.204.218.187,COLONIC ISCHEMIA causes SPONTANEOUS ISCHEMIC COLITIS,88,64,,115,80,causes,0.304997140665209,900053-FS1-4,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA,RO-cause_of
503223351,7/15/2014 15:22:43,,1323621365,7/15/2014 15:22:07,prodege,0.5683,7899370,USA,MI,Bay City,71.13.81.162,no_relation,88,64,,115,80,causes,0.304997140665209,900053-FS1-4,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA,RO-cause_of
503223351,7/15/2014 15:30:42,,1323626966,7/15/2014 15:30:24,tremorgames,0.5508,24449707,CAN,QC,Laval,96.21.249.72,no_relation,88,64,,115,80,causes,0.304997140665209,900053-FS1-4,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA,RO-cause_of
503223351,7/15/2014 15:49:33,,1323640902,7/15/2014 15:49:21,clixsense,0.6403,7265596,USA,IA,Neola,199.120.116.136,COLONIC ISCHEMIA causes SPONTANEOUS ISCHEMIC COLITIS,88,64,,115,80,causes,0.304997140665209,900053-FS1-4,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA,RO-cause_of
503223351,7/15/2014 16:46:01,,1323696497,7/15/2014 16:45:51,prodege,0.474,2143114,CAN,BC,Vancouver,24.84.160.12,SPONTANEOUS ISCHEMIC COLITIS causes COLONIC ISCHEMIA,88,64,,115,80,causes,0.304997140665209,900053-FS1-4,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA,RO-cause_of
503223351,7/15/2014 16:55:16,,1323706448,7/15/2014 16:54:45,prodege,0.5952,9525153,CAN,ON,Toronto,65.95.187.40,SPONTANEOUS ISCHEMIC COLITIS causes COLONIC ISCHEMIA,88,64,,115,80,causes,0.304997140665209,900053-FS1-4,"Evidence: ? A retrospective study showed that the nature of the COLONIC ISCHEMIA (i.e., SPONTANEOUS ISCHEMIC COLITIS versus ischemia related to shock from other disease) is predictive of mortality.",SPONTANEOUS ISCHEMIC COLITIS,COLONIC ISCHEMIA,RO-cause_of
503223352,7/15/2014 10:08:18,,1323475653,7/15/2014 10:07:51,eup_slw,0.9167,20818028,GBR,A7,Birmingham,92.232.139.254,INDUCED NAUSEA AND VOMITING causes ANTIEMETICS,78,135,,104,146,causes,0.603022689155527,907406-FS1-4,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS,RO-may_prevent
503223352,7/15/2014 10:27:53,,1323487783,7/15/2014 10:27:33,clixsense,0.8472,19803139,NLD,06,Veldhoven,212.61.84.196,ANTIEMETICS causes INDUCED NAUSEA AND VOMITING,78,135,,104,146,causes,0.603022689155527,907406-FS1-4,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS,RO-may_prevent
503223352,7/15/2014 10:29:46,,1323489011,7/15/2014 10:29:10,vivatic,0.8056,25451531,GBR,"","",83.67.28.193,no_relation,78,135,,104,146,causes,0.603022689155527,907406-FS1-4,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS,RO-may_prevent
503223352,7/15/2014 13:49:32,,1323586622,7/15/2014 13:48:52,prodege,0.6706,13795372,CAN,NS,Dartmouth,142.68.155.182,ANTIEMETICS causes INDUCED NAUSEA AND VOMITING,78,135,,104,146,causes,0.603022689155527,907406-FS1-4,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS,RO-may_prevent
503223352,7/15/2014 14:11:27,,1323592768,7/15/2014 14:11:07,neodev,0.4365,28336203,USA,PA,Harrisburg,50.149.53.150,ANTIEMETICS causes INDUCED NAUSEA AND VOMITING,78,135,,104,146,causes,0.603022689155527,907406-FS1-4,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS,RO-may_prevent
503223352,7/15/2014 15:21:11,,1323620302,7/15/2014 15:20:35,prodege,0.5683,7899370,USA,MI,Bay City,71.13.81.162,INDUCED NAUSEA AND VOMITING causes ANTIEMETICS,78,135,,104,146,causes,0.603022689155527,907406-FS1-4,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS,RO-may_prevent
503223352,7/15/2014 15:31:21,,1323627459,7/15/2014 15:31:06,tremorgames,0.5508,24449707,CAN,QC,Laval,96.21.249.72,ANTIEMETICS causes INDUCED NAUSEA AND VOMITING,78,135,,104,146,causes,0.603022689155527,907406-FS1-4,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS,RO-may_prevent
503223353,7/15/2014 10:27:53,,1323487790,7/15/2014 10:27:33,clixsense,0.8472,19803139,NLD,06,Veldhoven,212.61.84.196,LIVER is location of HEPATOCELLULAR NECROSIS,134,56,,138,79,is location of,0.964901281354015,905398-FS1-9,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS,RO-has_finding_site
503223353,7/15/2014 11:13:09,,1323519555,7/15/2014 11:12:26,prodege,0.7681,11864493,GBR,Z4,Wrexham,212.219.196.69,LIVER is location of HEPATOCELLULAR NECROSIS,134,56,,138,79,is location of,0.964901281354015,905398-FS1-9,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS,RO-has_finding_site
503223353,7/15/2014 11:18:02,,1323522685,7/15/2014 11:17:33,instagc,0.7264,24252915,GBR,B7,Bristol,77.98.139.82,LIVER is location of HEPATOCELLULAR NECROSIS,134,56,,138,79,is location of,0.964901281354015,905398-FS1-9,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS,RO-has_finding_site
503223353,7/15/2014 12:36:04,,1323560221,7/15/2014 12:34:54,prodege,0.5236,1852770,USA,TX,Abilene,76.198.102.54,LIVER is location of HEPATOCELLULAR NECROSIS,134,56,,138,79,is location of,0.964901281354015,905398-FS1-9,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS,RO-has_finding_site
503223353,7/15/2014 14:21:12,,1323595590,7/15/2014 14:20:45,instagc,0.6554,19636746,USA,NY,Andover,192.182.216.225,LIVER is location of HEPATOCELLULAR NECROSIS,134,56,,138,79,is location of,0.964901281354015,905398-FS1-9,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS,RO-has_finding_site
503223353,7/15/2014 14:32:35,,1323598995,7/15/2014 14:32:30,neodev,0.3913,25224036,CAN,ON,Sudbury,67.204.218.187,HEPATOCELLULAR NECROSIS is location of LIVER,134,56,,138,79,is location of,0.964901281354015,905398-FS1-9,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS,RO-has_finding_site
503223353,7/15/2014 15:20:08,,1323619623,7/15/2014 15:19:47,prodege,0.5683,7899370,USA,MI,Bay City,71.13.81.162,LIVER is location of HEPATOCELLULAR NECROSIS,134,56,,138,79,is location of,0.964901281354015,905398-FS1-9,"Furthermore, histological analyses verified significant HEPATOCELLULAR NECROSIS as well as enhanced myeloperoxidase staining in these LIVER specimens.",LIVER,HEPATOCELLULAR NECROSIS,RO-has_finding_site
503223354,7/15/2014 10:50:56,,1323503684,7/15/2014 10:50:40,clixsense,0.8486,27793793,GBR,C5,Chester,151.230.27.155,no_relation,52,5,,79,26,causes,0.377964473009227,900137-FS1-4,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,RO-cause_of
503223354,7/15/2014 10:52:13,,1323504641,7/15/2014 10:51:52,rewardsspot,0.6319,17763704,USA,VA,Manassas,198.7.62.204,HYPEROSMOLAR NONKETOTIC COMA causes DIABETIC KETOACIDOSIS,52,5,,79,26,causes,0.377964473009227,900137-FS1-4,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,RO-cause_of
503223354,7/15/2014 11:11:43,,1323518570,7/15/2014 11:11:05,elite,0.7417,28397222,GBR,Y4,Usk,31.50.223.75,no_relation,52,5,,79,26,causes,0.377964473009227,900137-FS1-4,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,RO-cause_of
503223354,7/15/2014 11:14:47,,1323520518,7/15/2014 11:14:19,prodege,0.7681,11864493,GBR,Z4,Wrexham,212.219.196.69,no_relation,52,5,,79,26,causes,0.377964473009227,900137-FS1-4,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,RO-cause_of
503223354,7/15/2014 13:32:04,,1323580874,7/15/2014 13:31:06,instagc,0.5063,23149109,USA,NC,Cary,24.206.38.18,DIABETIC KETOACIDOSIS causes HYPEROSMOLAR NONKETOTIC COMA,52,5,,79,26,causes,0.377964473009227,900137-FS1-4,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,RO-cause_of
503223354,7/15/2014 14:32:49,,1323599081,7/15/2014 14:32:43,neodev,0.3913,25224036,CAN,ON,Sudbury,67.204.218.187,DIABETIC KETOACIDOSIS causes HYPEROSMOLAR NONKETOTIC COMA,52,5,,79,26,causes,0.377964473009227,900137-FS1-4,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,RO-cause_of
503223354,7/15/2014 16:24:47,,1323671019,7/15/2014 16:24:00,clixsense,0.475,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,52,5,,79,26,causes,0.377964473009227,900137-FS1-4,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS,RO-cause_of
503223355,7/15/2014 10:28:36,,1323488307,7/15/2014 10:28:14,clixsense,0.8472,19803139,NLD,06,Veldhoven,212.61.84.196,ELEVATED BLOOD PRESSURE causes THE ACCELERATION OF HYPERTENSION,165,216,,187,248,causes,0.971285862357264,904990-FS1-4,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION,RO-has_definitional_manifestation
503223355,7/15/2014 10:31:36,,1323490268,7/15/2014 10:31:28,clixsense,0.6875,19162475,GBR,M3,Frome,82.33.126.30,ELEVATED BLOOD PRESSURE causes THE ACCELERATION OF HYPERTENSION,165,216,,187,248,causes,0.971285862357264,904990-FS1-4,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION,RO-has_definitional_manifestation
503223355,7/15/2014 10:51:17,,1323503984,7/15/2014 10:51:01,rewardsspot,0.6319,17763704,USA,VA,Manassas,198.7.62.204,ELEVATED BLOOD PRESSURE causes THE ACCELERATION OF HYPERTENSION,165,216,,187,248,causes,0.971285862357264,904990-FS1-4,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION,RO-has_definitional_manifestation
503223355,7/15/2014 11:25:17,,1323526797,7/15/2014 11:24:48,prodege,0.7792,15439740,AUS,02,Jannali,27.96.208.89,ELEVATED BLOOD PRESSURE causes THE ACCELERATION OF HYPERTENSION,165,216,,187,248,causes,0.971285862357264,904990-FS1-4,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION,RO-has_definitional_manifestation
503223355,7/15/2014 12:40:12,,1323561782,7/15/2014 12:39:58,instagc,0.7472,18960682,GBR,"","",86.29.147.112,ELEVATED BLOOD PRESSURE causes THE ACCELERATION OF HYPERTENSION,165,216,,187,248,causes,0.971285862357264,904990-FS1-4,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION,RO-has_definitional_manifestation
503223355,7/15/2014 13:05:01,,1323571645,7/15/2014 13:04:52,clixsense,0.601,20614047,USA,ID,Priest River,174.32.160.124,ELEVATED BLOOD PRESSURE causes THE ACCELERATION OF HYPERTENSION,165,216,,187,248,causes,0.971285862357264,904990-FS1-4,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION,RO-has_definitional_manifestation
503223355,7/15/2014 15:31:05,,1323627270,7/15/2014 15:30:56,tremorgames,0.5508,24449707,CAN,QC,Laval,96.21.249.72,THE ACCELERATION OF HYPERTENSION causes ELEVATED BLOOD PRESSURE,165,216,,187,248,causes,0.971285862357264,904990-FS1-4,"In addition, the decrease in granularity of the RIC in the presence of extensive renal arteriolar and arterial damage suggests reduced ability to compensate for the ELEVATED BLOOD PRESSURE and thus may contribute to THE ACCELERATION OF HYPERTENSION",ELEVATED BLOOD PRESSURE,THE ACCELERATION OF HYPERTENSION,RO-has_definitional_manifestation
503223356,7/15/2014 10:18:14,,1323481565,7/15/2014 10:17:19,gifthulk,0.9583,22144176,GBR,U8,Edinburgh,129.215.149.99,no_relation,37,108,,90,120,causes,0.530330085889911,902461-FS1-4,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503223356,7/15/2014 11:24:45,,1323526567,7/15/2014 11:24:27,prodege,0.7792,15439740,AUS,02,Jannali,27.96.208.89,OSTEOPOROSIS causes CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,37,108,,90,120,causes,0.530330085889911,902461-FS1-4,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503223356,7/15/2014 12:27:08,,1323557016,7/15/2014 12:26:29,prodege,0.6058,27934334,GBR,B9,High Wycombe,86.166.72.139,no_relation,37,108,,90,120,causes,0.530330085889911,902461-FS1-4,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503223356,7/15/2014 13:04:49,,1323571572,7/15/2014 13:04:39,clixsense,0.601,20614047,USA,ID,Priest River,174.32.160.124,no_relation,37,108,,90,120,causes,0.530330085889911,902461-FS1-4,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503223356,7/15/2014 13:10:33,,1323573705,7/15/2014 13:10:06,neodev,0.4365,28336203,USA,PA,Harrisburg,50.149.53.150,no_relation,37,108,,90,120,causes,0.530330085889911,902461-FS1-4,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503223356,7/15/2014 16:46:08,,1323696629,7/15/2014 16:46:02,prodege,0.474,2143114,CAN,BC,Vancouver,24.84.160.12,CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS causes OSTEOPOROSIS,37,108,,90,120,causes,0.530330085889911,902461-FS1-4,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503223356,7/15/2014 16:49:26,,1323700213,7/15/2014 16:48:47,prodege,0.5758,23541832,USA,AZ,Tempe,149.169.145.144,no_relation,37,108,,90,120,causes,0.530330085889911,902461-FS1-4,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503223357,7/15/2014 11:26:31,,1323527410,7/15/2014 11:26:15,instagc,0.7611,28301350,GBR,K4,Plymouth,92.28.215.248,CLONIDINE treats TAMOXIFEN ASSOCIATED HOT FLASHES,37,0,,68,9,treats,0.991836598134176,907723-FS1-2,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE,RO-may_treat
503223357,7/15/2014 11:27:54,,1323528272,7/15/2014 11:27:20,elite,0.7417,28397222,GBR,Y4,Usk,31.50.223.75,CLONIDINE treats TAMOXIFEN ASSOCIATED HOT FLASHES,37,0,,68,9,treats,0.991836598134176,907723-FS1-2,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE,RO-may_treat
503223357,7/15/2014 14:28:03,,1323597621,7/15/2014 14:27:45,elite,0.6381,28276268,USA,FL,Boynton Beach,99.114.225.45,CLONIDINE treats TAMOXIFEN ASSOCIATED HOT FLASHES,37,0,,68,9,treats,0.991836598134176,907723-FS1-2,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE,RO-may_treat
503223357,7/15/2014 15:49:20,,1323640787,7/15/2014 15:49:08,clixsense,0.6403,7265596,USA,IA,Neola,199.120.116.136,TAMOXIFEN ASSOCIATED HOT FLASHES treats CLONIDINE,37,0,,68,9,treats,0.991836598134176,907723-FS1-2,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE,RO-may_treat
503223357,7/15/2014 15:51:47,,1323642689,7/15/2014 15:51:26,neodev,0.624,14861092,GBR,I2,Manchester,90.194.137.76,CLONIDINE treats TAMOXIFEN ASSOCIATED HOT FLASHES,37,0,,68,9,treats,0.991836598134176,907723-FS1-2,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE,RO-may_treat
503223357,7/15/2014 16:45:19,,1323695563,7/15/2014 16:45:05,prodege,0.474,2143114,CAN,BC,Vancouver,24.84.160.12,CLONIDINE treats TAMOXIFEN ASSOCIATED HOT FLASHES,37,0,,68,9,treats,0.991836598134176,907723-FS1-2,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE,RO-may_treat
503223357,7/15/2014 16:53:39,,1323704703,7/15/2014 16:53:04,prodege,0.5952,9525153,CAN,ON,Toronto,65.95.187.40,CLONIDINE treats TAMOXIFEN ASSOCIATED HOT FLASHES,37,0,,68,9,treats,0.991836598134176,907723-FS1-2,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE,RO-may_treat
503223358,7/15/2014 11:16:15,,1323521435,7/15/2014 11:15:45,clixsense,0.8306,27871219,NLD,07,Amsterdam,87.210.207.223,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN diagnosed by ADMINISTRATION OF THE DRUG AFTER THE TEST,153,68,,193,113,diagnosed by,0.742781352708207,903512-FS1-13,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223358,7/15/2014 11:25:54,,1323527109,7/15/2014 11:25:32,prodege,0.7792,15439740,AUS,02,Jannali,27.96.208.89,no_relation,153,68,,193,113,diagnosed by,0.742781352708207,903512-FS1-13,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223358,7/15/2014 11:39:44,,1323535083,7/15/2014 11:39:14,clixsense,0.5726,23233834,GBR,N6,Sunderland,86.17.58.181,ADMINISTRATION OF THE DRUG AFTER THE TEST diagnosed by AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,153,68,,193,113,diagnosed by,0.742781352708207,903512-FS1-13,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223358,7/15/2014 11:48:57,,1323540365,7/15/2014 11:48:30,neodev,0.6637,21515166,NLD,11,Nootdorp,83.86.58.179,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN diagnosed by ADMINISTRATION OF THE DRUG AFTER THE TEST,153,68,,193,113,diagnosed by,0.742781352708207,903512-FS1-13,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223358,7/15/2014 11:53:11,,1323543427,7/15/2014 11:52:58,neodev,0.6736,24578640,USA,IL,Chicago,65.60.20.66,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN diagnosed by ADMINISTRATION OF THE DRUG AFTER THE TEST,153,68,,193,113,diagnosed by,0.742781352708207,903512-FS1-13,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223358,7/15/2014 13:04:49,,1323571571,7/15/2014 13:04:39,clixsense,0.601,20614047,USA,ID,Priest River,174.32.160.124,no_relation,153,68,,193,113,diagnosed by,0.742781352708207,903512-FS1-13,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223358,7/15/2014 13:30:41,,1323580503,7/15/2014 13:30:02,instagc,0.5063,23149109,USA,NC,Cary,24.206.38.18,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN diagnosed by ADMINISTRATION OF THE DRUG AFTER THE TEST,153,68,,193,113,diagnosed by,0.742781352708207,903512-FS1-13,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223359,7/15/2014 10:28:13,,1323488031,7/15/2014 10:27:54,clixsense,0.8472,19803139,NLD,06,Veldhoven,212.61.84.196,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,13,56,,49,66,treats,0.991836598134176,907635-FS1-2,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN,RO-may_treat
503223359,7/15/2014 10:51:49,,1323504417,7/15/2014 10:51:22,rewardsspot,0.6319,17763704,USA,VA,Manassas,198.7.62.204,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,13,56,,49,66,treats,0.991836598134176,907635-FS1-2,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN,RO-may_treat
503223359,7/15/2014 12:23:21,,1323555569,7/15/2014 12:22:36,paiddailysurveys,0.6127,11786001,USA,NC,Charlotte,71.28.89.238,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,13,56,,49,66,treats,0.991836598134176,907635-FS1-2,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN,RO-may_treat
503223359,7/15/2014 15:20:08,,1323619622,7/15/2014 15:19:47,prodege,0.5683,7899370,USA,MI,Bay City,71.13.81.162,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,13,56,,49,66,treats,0.991836598134176,907635-FS1-2,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN,RO-may_treat
503223359,7/15/2014 16:47:18,,1323697941,7/15/2014 16:47:01,clixsense,0.881,6455807,CAN,BC,Victoria,96.54.172.117,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,13,56,,49,66,treats,0.991836598134176,907635-FS1-2,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN,RO-may_treat
503223359,7/15/2014 16:50:33,,1323701456,7/15/2014 16:50:09,prodege,0.5758,23541832,USA,AZ,Tempe,149.169.145.144,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,13,56,,49,66,treats,0.991836598134176,907635-FS1-2,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN,RO-may_treat
503223359,7/15/2014 16:55:59,,1323707305,7/15/2014 16:55:42,prodege,0.5952,9525153,CAN,ON,Toronto,65.95.187.40,LOVASTATIN treats PRIMARY MODERATE HYPERCHOLESTEROLEMIA,13,56,,49,66,treats,0.991836598134176,907635-FS1-2,Treatment of PRIMARY MODERATE HYPERCHOLESTEROLEMIA with LOVASTATIN (mevinolin) and colestipol.,PRIMARY MODERATE HYPERCHOLESTEROLEMIA,LOVASTATIN,RO-may_treat
503223360,7/15/2014 10:26:02,,1323486531,7/15/2014 10:25:36,rewardsspot,0.8889,24482174,GBR,H9,London,46.23.68.180,BONE MARROW is location of LEUKEMIA,78,152,,88,160,is location of,0.977355554850442,902192-FS1-9,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA,RO-disease_has_primary_anatomic_site
503223360,7/15/2014 10:28:54,,1323488492,7/15/2014 10:28:37,clixsense,0.8472,19803139,NLD,06,Veldhoven,212.61.84.196,BONE MARROW is location of LEUKEMIA,78,152,,88,160,is location of,0.977355554850442,902192-FS1-9,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA,RO-disease_has_primary_anatomic_site
503223360,7/15/2014 10:52:13,,1323504644,7/15/2014 10:51:52,rewardsspot,0.6319,17763704,USA,VA,Manassas,198.7.62.204,BONE MARROW is location of LEUKEMIA,78,152,,88,160,is location of,0.977355554850442,902192-FS1-9,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA,RO-disease_has_primary_anatomic_site
503223360,7/15/2014 11:12:47,,1323519309,7/15/2014 11:12:01,prodege,0.6058,27934334,GBR,B9,High Wycombe,86.166.72.139,no_relation,78,152,,88,160,is location of,0.977355554850442,902192-FS1-9,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA,RO-disease_has_primary_anatomic_site
503223360,7/15/2014 11:13:48,,1323519980,7/15/2014 11:13:11,prodege,0.7681,11864493,GBR,Z4,Wrexham,212.219.196.69,no_relation,78,152,,88,160,is location of,0.977355554850442,902192-FS1-9,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA,RO-disease_has_primary_anatomic_site
503223360,7/15/2014 11:15:43,,1323521094,7/15/2014 11:15:19,clixsense,0.8306,27871219,NLD,07,Amsterdam,87.210.207.223,BONE MARROW is location of LEUKEMIA,78,152,,88,160,is location of,0.977355554850442,902192-FS1-9,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA,RO-disease_has_primary_anatomic_site
503223360,7/15/2014 11:49:17,,1323540515,7/15/2014 11:48:57,neodev,0.6637,21515166,NLD,11,Nootdorp,83.86.58.179,BONE MARROW is location of LEUKEMIA,78,152,,88,160,is location of,0.977355554850442,902192-FS1-9,Short  and long term co cultures of 49 cases of human osteosarcoma cells with BONE MARROW or peripheral blood cells of patients with different types of LEUKEMIA were studied.,BONE MARROW,LEUKEMIA,RO-disease_has_primary_anatomic_site
503223361,7/15/2014 10:24:47,,1323485703,7/15/2014 10:24:06,rewardsspot,0.8889,24482174,GBR,H9,London,46.23.68.180,MELPHALAN treats MULTIPLE MYELOMA,75,32,,90,41,treats,0.970494958830946,907938-FS1-2,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN,RO-may_treat
503223361,7/15/2014 11:27:19,,1323527951,7/15/2014 11:26:47,elite,0.7417,28397222,GBR,Y4,Usk,31.50.223.75,MELPHALAN treats MULTIPLE MYELOMA,75,32,,90,41,treats,0.970494958830946,907938-FS1-2,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN,RO-may_treat
503223361,7/15/2014 11:50:29,,1323541441,7/15/2014 11:50:12,neodev,0.6637,21515166,NLD,11,Nootdorp,83.86.58.179,MELPHALAN treats MULTIPLE MYELOMA,75,32,,90,41,treats,0.970494958830946,907938-FS1-2,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN,RO-may_treat
503223361,7/15/2014 13:48:47,,1323586485,7/15/2014 13:48:17,prodege,0.6706,13795372,CAN,NS,Dartmouth,142.68.155.182,MELPHALAN treats MULTIPLE MYELOMA,75,32,,90,41,treats,0.970494958830946,907938-FS1-2,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN,RO-may_treat
503223361,7/15/2014 13:51:07,,1323587098,7/15/2014 13:50:45,neodev,0.4671,18339121,USA,SC,Sumter,173.93.188.194,MELPHALAN treats MULTIPLE MYELOMA,75,32,,90,41,treats,0.970494958830946,907938-FS1-2,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN,RO-may_treat
503223361,7/15/2014 15:49:07,,1323640573,7/15/2014 15:48:52,clixsense,0.6403,7265596,USA,IA,Neola,199.120.116.136,MELPHALAN treats MULTIPLE MYELOMA,75,32,,90,41,treats,0.970494958830946,907938-FS1-2,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN,RO-may_treat
503223361,7/15/2014 15:53:00,,1323643543,7/15/2014 15:52:38,neodev,0.624,14861092,GBR,I2,Manchester,90.194.137.76,MELPHALAN treats MULTIPLE MYELOMA,75,32,,90,41,treats,0.970494958830946,907938-FS1-2,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN,RO-may_treat
503223362,7/15/2014 10:31:44,,1323490374,7/15/2014 10:31:37,clixsense,0.6875,19162475,GBR,M3,Frome,82.33.126.30,PANIC DISORDER causes PANIC ATTACKS,64,166,,76,180,causes,0.738548945875996,904519-FS1-4,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER,RO-has_definitional_manifestation
503223362,7/15/2014 11:14:57,,1323520643,7/15/2014 11:14:11,prodege,0.6058,27934334,GBR,B9,High Wycombe,86.166.72.139,no_relation,64,166,,76,180,causes,0.738548945875996,904519-FS1-4,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER,RO-has_definitional_manifestation
503223362,7/15/2014 12:04:58,,1323548697,7/15/2014 12:04:31,prodege,0.35,7664351,USA,NY,Cicero,74.111.0.21,PANIC DISORDER causes PANIC ATTACKS,64,166,,76,180,causes,0.738548945875996,904519-FS1-4,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER,RO-has_definitional_manifestation
503223362,7/15/2014 12:58:53,,1323569288,7/15/2014 12:58:40,elite,0.8028,28503042,USA,NJ,Woodbridge,54.191.150.115,PANIC DISORDER causes PANIC ATTACKS,64,166,,76,180,causes,0.738548945875996,904519-FS1-4,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER,RO-has_definitional_manifestation
503223362,7/15/2014 15:49:20,,1323640785,7/15/2014 15:49:08,clixsense,0.6403,7265596,USA,IA,Neola,199.120.116.136,PANIC DISORDER causes PANIC ATTACKS,64,166,,76,180,causes,0.738548945875996,904519-FS1-4,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER,RO-has_definitional_manifestation
503223362,7/15/2014 16:59:40,,1323711846,7/15/2014 16:59:26,neodev,0.6701,18755947,GBR,H2,Accrington,80.47.185.52,PANIC DISORDER causes PANIC ATTACKS,64,166,,76,180,causes,0.738548945875996,904519-FS1-4,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER,RO-has_definitional_manifestation
503223362,7/15/2014 17:06:39,,1323718638,7/15/2014 17:06:21,instagc,0.9286,19004168,GBR,H2,Accrington,80.47.185.52,PANIC DISORDER causes PANIC ATTACKS,64,166,,76,180,causes,0.738548945875996,904519-FS1-4,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER,RO-has_definitional_manifestation
503223363,7/15/2014 10:06:03,,1323474386,7/15/2014 10:05:09,eup_slw,0.9167,20818028,GBR,A7,Birmingham,92.232.139.254,no_relation,66,103,,70,111,is location of,0.529812942826018,902366-FS1-9,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY,RO-disease_has_primary_anatomic_site
503223363,7/15/2014 10:51:49,,1323504414,7/15/2014 10:51:22,rewardsspot,0.6319,17763704,USA,VA,Manassas,198.7.62.204,BRAIN is location of EPILEPSY,66,103,,70,111,is location of,0.529812942826018,902366-FS1-9,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY,RO-disease_has_primary_anatomic_site
503223363,7/15/2014 11:03:55,,1323511880,7/15/2014 11:03:34,prodege,0.6528,28039757,GBR,L8,Southport,109.155.158.54,BRAIN is location of EPILEPSY,66,103,,70,111,is location of,0.529812942826018,902366-FS1-9,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY,RO-disease_has_primary_anatomic_site
503223363,7/15/2014 11:48:29,,1323540106,7/15/2014 11:48:15,neodev,0.6637,21515166,NLD,11,Nootdorp,83.86.58.179,EPILEPSY is location of BRAIN,66,103,,70,111,is location of,0.529812942826018,902366-FS1-9,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY,RO-disease_has_primary_anatomic_site
503223363,7/15/2014 12:38:11,,1323561084,7/15/2014 12:37:40,prodege,0.5236,1852770,USA,TX,Abilene,76.198.102.54,EPILEPSY is location of BRAIN,66,103,,70,111,is location of,0.529812942826018,902366-FS1-9,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY,RO-disease_has_primary_anatomic_site
503223363,7/15/2014 12:57:58,,1323568815,7/15/2014 12:57:35,elite,0.8028,28503042,USA,NJ,Woodbridge,54.191.150.115,no_relation,66,103,,70,111,is location of,0.529812942826018,902366-FS1-9,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY,RO-disease_has_primary_anatomic_site
503223363,7/15/2014 13:48:07,,1323586299,7/15/2014 13:47:31,prodege,0.6706,13795372,CAN,NS,Dartmouth,142.68.155.182,BRAIN is location of EPILEPSY,66,103,,70,111,is location of,0.529812942826018,902366-FS1-9,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY,RO-disease_has_primary_anatomic_site
503223364,7/15/2014 10:06:49,,1323474854,7/15/2014 10:06:05,eup_slw,0.9167,20818028,GBR,A7,Birmingham,92.232.139.254,no_relation,87,18,,109,31,causes,0.970494958830946,903519-FS1-4,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS,RO-has_causative_agent
503223364,7/15/2014 10:08:52,,1323475968,7/15/2014 10:08:31,clixsense,0.875,15189335,GBR,E4,Colchester,5.67.141.89,MONONUCLEOSIS causes EPSTEIN BARR VIRUS (EBV,87,18,,109,31,causes,0.970494958830946,903519-FS1-4,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS,RO-has_causative_agent
503223364,7/15/2014 10:52:42,,1323504933,7/15/2014 10:52:15,rewardsspot,0.6319,17763704,USA,VA,Manassas,198.7.62.204,EPSTEIN BARR VIRUS (EBV causes MONONUCLEOSIS,87,18,,109,31,causes,0.970494958830946,903519-FS1-4,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS,RO-has_causative_agent
503223364,7/15/2014 12:12:14,,1323551174,7/15/2014 12:11:45,paiddailysurveys,0.6127,11786001,USA,NC,Charlotte,71.28.89.238,MONONUCLEOSIS causes EPSTEIN BARR VIRUS (EBV,87,18,,109,31,causes,0.970494958830946,903519-FS1-4,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS,RO-has_causative_agent
503223364,7/15/2014 12:36:57,,1323560596,7/15/2014 12:36:40,prodege,0.5236,1852770,USA,TX,Abilene,76.198.102.54,EPSTEIN BARR VIRUS (EBV causes MONONUCLEOSIS,87,18,,109,31,causes,0.970494958830946,903519-FS1-4,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS,RO-has_causative_agent
503223364,7/15/2014 13:46:49,,1323585933,7/15/2014 13:46:20,prodege,0.6706,13795372,CAN,NS,Dartmouth,142.68.155.182,no_relation,87,18,,109,31,causes,0.970494958830946,903519-FS1-4,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS,RO-has_causative_agent
503223364,7/15/2014 15:51:47,,1323642670,7/15/2014 15:51:26,neodev,0.624,14861092,GBR,I2,Manchester,90.194.137.76,EPSTEIN BARR VIRUS (EBV causes MONONUCLEOSIS,87,18,,109,31,causes,0.970494958830946,903519-FS1-4,"Two patients with MONONUCLEOSIS one due to cytomegalovirus (CMV), and the other due to EPSTEIN BARR VIRUS (EBV presenting with high fever, malaise and hepatitis, had granulomas in the bone marrow but not in the liver.",EPSTEIN BARR VIRUS (EBV,MONONUCLEOSIS,RO-has_causative_agent
503223365,7/15/2014 11:19:46,,1323523784,7/15/2014 11:19:01,instagc,0.8431,13763729,USA,"","",75.182.89.225,THE TREATMENT OF VULVODYNIA FOUND THAT 17 treats ROBUST REDUCTION IN PAIN,124,49,,147,90,treats,0.848528137423857,904958-FS1-2,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17,RO-has_definitional_manifestation
503223365,7/15/2014 11:25:17,,1323526788,7/15/2014 11:24:48,prodege,0.7792,15439740,AUS,02,Jannali,27.96.208.89,THE TREATMENT OF VULVODYNIA FOUND THAT 17 treats ROBUST REDUCTION IN PAIN,124,49,,147,90,treats,0.848528137423857,904958-FS1-2,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17,RO-has_definitional_manifestation
503223365,7/15/2014 11:27:47,,1323528209,7/15/2014 11:27:32,instagc,0.7611,28301350,GBR,K4,Plymouth,92.28.215.248,THE TREATMENT OF VULVODYNIA FOUND THAT 17 treats ROBUST REDUCTION IN PAIN,124,49,,147,90,treats,0.848528137423857,904958-FS1-2,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17,RO-has_definitional_manifestation
503223365,7/15/2014 11:49:17,,1323540513,7/15/2014 11:48:57,neodev,0.6637,21515166,NLD,11,Nootdorp,83.86.58.179,THE TREATMENT OF VULVODYNIA FOUND THAT 17 treats ROBUST REDUCTION IN PAIN,124,49,,147,90,treats,0.848528137423857,904958-FS1-2,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17,RO-has_definitional_manifestation
503223365,7/15/2014 11:52:57,,1323543270,7/15/2014 11:52:34,neodev,0.6736,24578640,USA,IL,Chicago,65.60.20.66,THE TREATMENT OF VULVODYNIA FOUND THAT 17 treats ROBUST REDUCTION IN PAIN,124,49,,147,90,treats,0.848528137423857,904958-FS1-2,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17,RO-has_definitional_manifestation
503223365,7/15/2014 12:38:45,,1323561266,7/15/2014 12:38:12,prodege,0.5236,1852770,USA,TX,Abilene,76.198.102.54,no_relation,124,49,,147,90,treats,0.848528137423857,904958-FS1-2,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17,RO-has_definitional_manifestation
503223365,7/15/2014 14:32:29,,1323598970,7/15/2014 14:32:20,neodev,0.3913,25224036,CAN,ON,Sudbury,67.204.218.187,ROBUST REDUCTION IN PAIN treats THE TREATMENT OF VULVODYNIA FOUND THAT 17,124,49,,147,90,treats,0.848528137423857,904958-FS1-2,"? An open label, 8 week trial of lamotrigine for THE TREATMENT OF VULVODYNIA FOUND THAT 17 of 31 participants experienced a ROBUST REDUCTION IN PAIN ( 55.",ROBUST REDUCTION IN PAIN,THE TREATMENT OF VULVODYNIA FOUND THAT 17,RO-has_definitional_manifestation
503223366,7/15/2014 10:07:22,,1323475110,7/15/2014 10:06:51,eup_slw,0.9167,20818028,GBR,A7,Birmingham,92.232.139.254,no_relation,124,48,,148,86,causes,0.875189948987367,901512-FS1-4,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA,RO-disease_has_finding
503223366,7/15/2014 10:30:29,,1323489449,7/15/2014 10:29:47,vivatic,0.8056,25451531,GBR,"","",83.67.28.193,no_relation,124,48,,148,86,causes,0.875189948987367,901512-FS1-4,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA,RO-disease_has_finding
503223366,7/15/2014 11:14:29,,1323520379,7/15/2014 11:13:54,clixsense,0.8306,27871219,NLD,07,Amsterdam,87.210.207.223,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA causes COMPLICATION OF PREGNANCY,124,48,,148,86,causes,0.875189948987367,901512-FS1-4,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA,RO-disease_has_finding
503223366,7/15/2014 11:14:57,,1323520647,7/15/2014 11:14:11,prodege,0.6058,27934334,GBR,B9,High Wycombe,86.166.72.139,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA causes COMPLICATION OF PREGNANCY,124,48,,148,86,causes,0.875189948987367,901512-FS1-4,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA,RO-disease_has_finding
503223366,7/15/2014 15:22:06,,1323620924,7/15/2014 15:21:12,prodege,0.5683,7899370,USA,MI,Bay City,71.13.81.162,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA causes COMPLICATION OF PREGNANCY,124,48,,148,86,causes,0.875189948987367,901512-FS1-4,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA,RO-disease_has_finding
503223366,7/15/2014 15:52:08,,1323642974,7/15/2014 15:51:48,neodev,0.624,14861092,GBR,I2,Manchester,90.194.137.76,COMPLICATION OF PREGNANCY causes PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA,124,48,,148,86,causes,0.875189948987367,901512-FS1-4,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA,RO-disease_has_finding
503223366,7/15/2014 16:50:09,,1323701029,7/15/2014 16:49:28,prodege,0.5758,23541832,USA,AZ,Tempe,149.169.145.144,no_relation,124,48,,148,86,causes,0.875189948987367,901512-FS1-4,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA,RO-disease_has_finding
503223367,7/15/2014 11:14:09,,1323520178,7/15/2014 11:13:33,prodege,0.6058,27934334,GBR,B9,High Wycombe,86.166.72.139,INSULIN treats TYPE 2 DIABETES,57,146,,71,153,treats,0.755928946018454,908348-FS1-2,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN,RO-may_treat
503223367,7/15/2014 11:23:37,,1323525832,7/15/2014 11:23:16,prodege,0.7792,15439740,AUS,02,Jannali,27.96.208.89,INSULIN treats TYPE 2 DIABETES,57,146,,71,153,treats,0.755928946018454,908348-FS1-2,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN,RO-may_treat
503223367,7/15/2014 12:38:11,,1323561082,7/15/2014 12:37:40,prodege,0.5236,1852770,USA,TX,Abilene,76.198.102.54,no_relation,57,146,,71,153,treats,0.755928946018454,908348-FS1-2,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN,RO-may_treat
503223367,7/15/2014 12:38:52,,1323561347,7/15/2014 12:38:38,instagc,0.7472,18960682,GBR,"","",86.29.147.112,INSULIN treats TYPE 2 DIABETES,57,146,,71,153,treats,0.755928946018454,908348-FS1-2,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN,RO-may_treat
503223367,7/15/2014 13:52:40,,1323587498,7/15/2014 13:51:55,neodev,0.4671,18339121,USA,SC,Sumter,173.93.188.194,no_relation,57,146,,71,153,treats,0.755928946018454,908348-FS1-2,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN,RO-may_treat
503223367,7/15/2014 13:52:56,,1323587575,7/15/2014 13:51:37,clixsense,0.4333,6334612,USA,OH,Cleveland,108.225.254.58,INSULIN treats TYPE 2 DIABETES,57,146,,71,153,treats,0.755928946018454,908348-FS1-2,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN,RO-may_treat
503223367,7/15/2014 14:21:12,,1323595599,7/15/2014 14:20:45,instagc,0.6554,19636746,USA,NY,Andover,192.182.216.225,no_relation,57,146,,71,153,treats,0.755928946018454,908348-FS1-2,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN,RO-may_treat
503223368,7/15/2014 10:18:14,,1323481566,7/15/2014 10:17:19,gifthulk,0.9583,22144176,GBR,U8,Edinburgh,129.215.149.99,INSULIN GLARGINE treats TYPE 1 DIABETES,544,510,,558,526,treats,0.985329278164293,907694-FS1-2,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE,RO-may_treat
503223368,7/15/2014 11:19:00,,1323523359,7/15/2014 11:18:31,instagc,0.8431,13763729,USA,"","",75.182.89.225,INSULIN GLARGINE treats TYPE 1 DIABETES,544,510,,558,526,treats,0.985329278164293,907694-FS1-2,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE,RO-may_treat
503223368,7/15/2014 13:04:37,,1323571511,7/15/2014 13:04:27,clixsense,0.601,20614047,USA,ID,Priest River,174.32.160.124,TYPE 1 DIABETES treats INSULIN GLARGINE,544,510,,558,526,treats,0.985329278164293,907694-FS1-2,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE,RO-may_treat
503223368,7/15/2014 13:53:05,,1323587616,7/15/2014 13:52:42,neodev,0.4671,18339121,USA,SC,Sumter,173.93.188.194,TYPE 1 DIABETES treats INSULIN GLARGINE,544,510,,558,526,treats,0.985329278164293,907694-FS1-2,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE,RO-may_treat
503223368,7/15/2014 15:51:26,,1323642411,7/15/2014 15:51:01,neodev,0.624,14861092,GBR,I2,Manchester,90.194.137.76,INSULIN GLARGINE treats TYPE 1 DIABETES,544,510,,558,526,treats,0.985329278164293,907694-FS1-2,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE,RO-may_treat
503223368,7/15/2014 16:51:51,,1323702854,7/15/2014 16:51:17,prodege,0.5758,23541832,USA,AZ,Tempe,149.169.145.144,INSULIN GLARGINE treats TYPE 1 DIABETES,544,510,,558,526,treats,0.985329278164293,907694-FS1-2,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE,RO-may_treat
503223368,7/15/2014 16:55:16,,1323706447,7/15/2014 16:54:45,prodege,0.5952,9525153,CAN,ON,Toronto,65.95.187.40,INSULIN GLARGINE treats TYPE 1 DIABETES,544,510,,558,526,treats,0.985329278164293,907694-FS1-2,"Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects  Human epidermal growth factor enhances healing of diabetic foot ulcers  Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta analysis  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of INSULIN GLARGINE in patients with TYPE 1 DIABETES  Management of dyslipidemia in children and adolescents with diabetes  Low glycemic index diets in the management of diabetes: a meta analysis.",TYPE 1 DIABETES,INSULIN GLARGINE,RO-may_treat
503223369,7/15/2014 11:13:09,,1323519562,7/15/2014 11:12:26,prodege,0.7681,11864493,GBR,Z4,Wrexham,212.219.196.69,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT treats MULTIPLE MYELOMA,180,101,,195,156,treats,0.981980506061966,908005-FS1-2,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT,RO-may_treat
503223369,7/15/2014 13:49:32,,1323586616,7/15/2014 13:48:52,prodege,0.6706,13795372,CAN,NS,Dartmouth,142.68.155.182,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT treats MULTIPLE MYELOMA,180,101,,195,156,treats,0.981980506061966,908005-FS1-2,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT,RO-may_treat
503223369,7/15/2014 14:11:27,,1323592769,7/15/2014 14:11:07,neodev,0.4365,28336203,USA,PA,Harrisburg,50.149.53.150,no_relation,180,101,,195,156,treats,0.981980506061966,908005-FS1-2,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT,RO-may_treat
503223369,7/15/2014 14:20:09,,1323595310,7/15/2014 14:19:44,instagc,0.6554,19636746,USA,NY,Andover,192.182.216.225,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT treats MULTIPLE MYELOMA,180,101,,195,156,treats,0.981980506061966,908005-FS1-2,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT,RO-may_treat
503223369,7/15/2014 14:27:21,,1323597372,7/15/2014 14:26:59,elite,0.6381,28276268,USA,FL,Boynton Beach,99.114.225.45,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT treats MULTIPLE MYELOMA,180,101,,195,156,treats,0.981980506061966,908005-FS1-2,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT,RO-may_treat
503223369,7/15/2014 15:30:03,,1323626466,7/15/2014 15:29:43,tremorgames,0.5508,24449707,CAN,QC,Laval,96.21.249.72,no_relation,180,101,,195,156,treats,0.981980506061966,908005-FS1-2,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT,RO-may_treat
503223369,7/15/2014 16:25:57,,1323672417,7/15/2014 16:25:48,clixsense,0.475,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,180,101,,195,156,treats,0.981980506061966,908005-FS1-2,The clinical applicability of targeting proteasomes is exemplified by the recent FDA approval of the FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT of relapsed/refractory MULTIPLE MYELOMA,MULTIPLE MYELOMA,FIRST PROTEASOME INHIBITOR BORTEZOMIB FOR THE TREATMENT,RO-may_treat
503223370,7/15/2014 10:06:49,,1323474851,7/15/2014 10:06:05,eup_slw,0.9167,20818028,GBR,A7,Birmingham,92.232.139.254,ECTOPIC PREGNANCY causes COMPLICATIONS OF PREGNANCY,38,0,,63,17,causes,0.787561530648217,901953-FS1-4,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY,RO-disease_has_finding
503223370,7/15/2014 10:06:50,,1323474870,7/15/2014 10:06:29,clixsense,0.875,15189335,GBR,E4,Colchester,5.67.141.89,ECTOPIC PREGNANCY causes COMPLICATIONS OF PREGNANCY,38,0,,63,17,causes,0.787561530648217,901953-FS1-4,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY,RO-disease_has_finding
503223370,7/15/2014 10:31:44,,1323490372,7/15/2014 10:31:37,clixsense,0.6875,19162475,GBR,M3,Frome,82.33.126.30,COMPLICATIONS OF PREGNANCY causes ECTOPIC PREGNANCY,38,0,,63,17,causes,0.787561530648217,901953-FS1-4,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY,RO-disease_has_finding
503223370,7/15/2014 10:51:51,,1323504425,7/15/2014 10:51:39,clixsense,0.8486,27793793,GBR,C5,Chester,151.230.27.155,ECTOPIC PREGNANCY causes COMPLICATIONS OF PREGNANCY,38,0,,63,17,causes,0.787561530648217,901953-FS1-4,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY,RO-disease_has_finding
503223370,7/15/2014 11:19:02,,1323523370,7/15/2014 11:18:33,instagc,0.7264,24252915,GBR,B7,Bristol,77.98.139.82,ECTOPIC PREGNANCY causes COMPLICATIONS OF PREGNANCY,38,0,,63,17,causes,0.787561530648217,901953-FS1-4,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY,RO-disease_has_finding
503223370,7/15/2014 11:38:25,,1323534407,7/15/2014 11:37:56,clixsense,0.5726,23233834,GBR,N6,Sunderland,86.17.58.181,ECTOPIC PREGNANCY causes COMPLICATIONS OF PREGNANCY,38,0,,63,17,causes,0.787561530648217,901953-FS1-4,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY,RO-disease_has_finding
503223370,7/15/2014 13:30:41,,1323580502,7/15/2014 13:30:02,instagc,0.5063,23149109,USA,NC,Cary,24.206.38.18,ECTOPIC PREGNANCY causes COMPLICATIONS OF PREGNANCY,38,0,,63,17,causes,0.787561530648217,901953-FS1-4,ECTOPIC PREGNANCY is one of the major COMPLICATIONS OF PREGNANCY,COMPLICATIONS OF PREGNANCY,ECTOPIC PREGNANCY,RO-disease_has_finding
503223371,7/15/2014 10:24:00,,1323485308,7/15/2014 10:23:31,rewardsspot,0.8889,24482174,GBR,H9,London,46.23.68.180,ROCKY MOUNTAIN SPOTTED FEVER causes RICKETTSIA RICKETTSII,58,144,,78,172,causes,0.589767824619588,903784-FS1-4,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER,RO-has_causative_agent
503223371,7/15/2014 14:18:57,,1323594925,7/15/2014 14:18:21,instagc,0.6554,19636746,USA,NY,Andover,192.182.216.225,RICKETTSIA RICKETTSII causes ROCKY MOUNTAIN SPOTTED FEVER,58,144,,78,172,causes,0.589767824619588,903784-FS1-4,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER,RO-has_causative_agent
503223371,7/15/2014 15:49:33,,1323640901,7/15/2014 15:49:21,clixsense,0.6403,7265596,USA,IA,Neola,199.120.116.136,RICKETTSIA RICKETTSII causes ROCKY MOUNTAIN SPOTTED FEVER,58,144,,78,172,causes,0.589767824619588,903784-FS1-4,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER,RO-has_causative_agent
503223371,7/15/2014 16:25:02,,1323671394,7/15/2014 16:24:48,clixsense,0.475,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,58,144,,78,172,causes,0.589767824619588,903784-FS1-4,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER,RO-has_causative_agent
503223371,7/15/2014 16:50:50,,1323701796,7/15/2014 16:50:33,prodege,0.5758,23541832,USA,AZ,Tempe,149.169.145.144,no_relation,58,144,,78,172,causes,0.589767824619588,903784-FS1-4,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER,RO-has_causative_agent
503223371,7/15/2014 16:55:42,,1323706925,7/15/2014 16:55:17,prodege,0.5952,9525153,CAN,ON,Toronto,65.95.187.40,RICKETTSIA RICKETTSII causes ROCKY MOUNTAIN SPOTTED FEVER,58,144,,78,172,causes,0.589767824619588,903784-FS1-4,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER,RO-has_causative_agent
503223371,7/15/2014 16:58:45,,1323710628,7/15/2014 16:58:21,neodev,0.6701,18755947,GBR,H2,Accrington,80.47.185.52,no_relation,58,144,,78,172,causes,0.589767824619588,903784-FS1-4,A primer pair derived from the 17 kDa antigen sequence of RICKETTSIA RICKETTSII amplified specifically a 434 bp DNA fragment from the genome of ROCKY MOUNTAIN SPOTTED FEVER and endemic and epidemic typhus.,RICKETTSIA RICKETTSII,ROCKY MOUNTAIN SPOTTED FEVER,RO-has_causative_agent
503223372,7/15/2014 10:18:32,,1323481797,7/15/2014 10:18:15,gifthulk,0.9583,22144176,GBR,U8,Edinburgh,129.215.149.99,no_relation,44,80,,50,107,causes,0.992277876713668,902568-FS1-4,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY,RO-disease_may_have_finding
503223372,7/15/2014 11:19:00,,1323523360,7/15/2014 11:18:31,instagc,0.8431,13763729,USA,"","",75.182.89.225,no_relation,44,80,,50,107,causes,0.992277876713668,902568-FS1-4,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY,RO-disease_may_have_finding
503223372,7/15/2014 12:40:12,,1323561781,7/15/2014 12:39:58,instagc,0.7472,18960682,GBR,"","",86.29.147.112,no_relation,44,80,,50,107,causes,0.992277876713668,902568-FS1-4,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY,RO-disease_may_have_finding
503223372,7/15/2014 13:49:10,,1323586547,7/15/2014 13:48:14,neodev,0.4671,18339121,USA,SC,Sumter,173.93.188.194,ASCITES causes ADENOCARCINOMA OF THE OVARY,44,80,,50,107,causes,0.992277876713668,902568-FS1-4,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY,RO-disease_may_have_finding
503223372,7/15/2014 14:20:38,,1323595418,7/15/2014 14:20:13,instagc,0.6554,19636746,USA,NY,Andover,192.182.216.225,no_relation,44,80,,50,107,causes,0.992277876713668,902568-FS1-4,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY,RO-disease_may_have_finding
503223372,7/15/2014 14:28:03,,1323597622,7/15/2014 14:27:45,elite,0.6381,28276268,USA,FL,Boynton Beach,99.114.225.45,ASCITES causes ADENOCARCINOMA OF THE OVARY,44,80,,50,107,causes,0.992277876713668,902568-FS1-4,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY,RO-disease_may_have_finding
503223372,7/15/2014 15:22:06,,1323620938,7/15/2014 15:21:12,prodege,0.5683,7899370,USA,MI,Bay City,71.13.81.162,ASCITES causes ADENOCARCINOMA OF THE OVARY,44,80,,50,107,causes,0.992277876713668,902568-FS1-4,A 74 year old woman presented with moderate ASCITES with diagnostic features of ADENOCARCINOMA OF THE OVARY,ASCITES,ADENOCARCINOMA OF THE OVARY,RO-disease_may_have_finding
503223373,7/15/2014 10:07:22,,1323475111,7/15/2014 10:06:51,eup_slw,0.9167,20818028,GBR,A7,Birmingham,92.232.139.254,no_relation,13,78,,26,103,causes,0.848528137423857,906233-FS1-4,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE,RO-has_manifestation
503223373,7/15/2014 10:08:03,,1323475550,7/15/2014 10:07:28,clixsense,0.875,15189335,GBR,E4,Colchester,5.67.141.89,POLYCYSTIC KIDNEY DISEASE causes KIDNEY FAILURE,13,78,,26,103,causes,0.848528137423857,906233-FS1-4,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE,RO-has_manifestation
503223373,7/15/2014 10:24:00,,1323485309,7/15/2014 10:23:31,rewardsspot,0.8889,24482174,GBR,H9,London,46.23.68.180,POLYCYSTIC KIDNEY DISEASE causes KIDNEY FAILURE,13,78,,26,103,causes,0.848528137423857,906233-FS1-4,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE,RO-has_manifestation
503223373,7/15/2014 10:53:18,,1323505348,7/15/2014 10:52:46,rewardsspot,0.6319,17763704,USA,VA,Manassas,198.7.62.204,KIDNEY FAILURE causes POLYCYSTIC KIDNEY DISEASE,13,78,,26,103,causes,0.848528137423857,906233-FS1-4,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE,RO-has_manifestation
503223373,7/15/2014 12:36:38,,1323560479,7/15/2014 12:36:06,prodege,0.5236,1852770,USA,TX,Abilene,76.198.102.54,no_relation,13,78,,26,103,causes,0.848528137423857,906233-FS1-4,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE,RO-has_manifestation
503223373,7/15/2014 13:48:47,,1323586476,7/15/2014 13:48:17,prodege,0.6706,13795372,CAN,NS,Dartmouth,142.68.155.182,POLYCYSTIC KIDNEY DISEASE causes KIDNEY FAILURE,13,78,,26,103,causes,0.848528137423857,906233-FS1-4,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE,RO-has_manifestation
503223373,7/15/2014 14:33:03,,1323599185,7/15/2014 14:32:57,neodev,0.3913,25224036,CAN,ON,Sudbury,67.204.218.187,KIDNEY FAILURE causes POLYCYSTIC KIDNEY DISEASE,13,78,,26,103,causes,0.848528137423857,906233-FS1-4,"For example, KIDNEY FAILURE is rapid in diabetic nephropathy, intermediate in POLYCYSTIC KIDNEY DISEASE and slow in lithium nephropathy.",KIDNEY FAILURE,POLYCYSTIC KIDNEY DISEASE,RO-has_manifestation
503223374,7/15/2014 11:19:02,,1323523384,7/15/2014 11:18:33,instagc,0.7264,24252915,GBR,B7,Bristol,77.98.139.82,ADMINISTRATION OF THE DRUG AFTER THE TEST causes AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,153,68,,193,113,causes,0.371390676354104,903512-FS1-4,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223374,7/15/2014 11:19:46,,1323523780,7/15/2014 11:19:01,instagc,0.8431,13763729,USA,"","",75.182.89.225,no_relation,153,68,,193,113,causes,0.371390676354104,903512-FS1-4,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223374,7/15/2014 12:22:34,,1323555301,7/15/2014 12:21:40,paiddailysurveys,0.6127,11786001,USA,NC,Charlotte,71.28.89.238,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN causes ADMINISTRATION OF THE DRUG AFTER THE TEST,153,68,,193,113,causes,0.371390676354104,903512-FS1-4,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223374,7/15/2014 15:52:08,,1323642980,7/15/2014 15:51:48,neodev,0.624,14861092,GBR,I2,Manchester,90.194.137.76,no_relation,153,68,,193,113,causes,0.371390676354104,903512-FS1-4,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223374,7/15/2014 16:45:49,,1323696290,7/15/2014 16:45:39,prodege,0.474,2143114,CAN,BC,Vancouver,24.84.160.12,ADMINISTRATION OF THE DRUG AFTER THE TEST causes AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,153,68,,193,113,causes,0.371390676354104,903512-FS1-4,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223374,7/15/2014 16:49:26,,1323700210,7/15/2014 16:48:47,prodege,0.5758,23541832,USA,AZ,Tempe,149.169.145.144,no_relation,153,68,,193,113,causes,0.371390676354104,903512-FS1-4,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223374,7/15/2014 16:59:26,,1323711648,7/15/2014 16:59:00,neodev,0.6701,18755947,GBR,H2,Accrington,80.47.185.52,no_relation,153,68,,193,113,causes,0.371390676354104,903512-FS1-4,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223375,7/15/2014 10:19:55,,1323482835,7/15/2014 10:19:17,gifthulk,0.9583,22144176,GBR,U8,Edinburgh,129.215.149.99,URSODIOL treats GALLSTONES,92,42,,101,50,treats,0.971285862357264,907935-FS1-2,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL,RO-may_treat
503223375,7/15/2014 10:27:43,,1323487657,7/15/2014 10:27:07,vivatic,0.8056,25451531,GBR,"","",83.67.28.193,URSODIOL treats GALLSTONES,92,42,,101,50,treats,0.971285862357264,907935-FS1-2,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL,RO-may_treat
503223375,7/15/2014 10:31:28,,1323490198,7/15/2014 10:31:07,clixsense,0.6875,19162475,GBR,M3,Frome,82.33.126.30,URSODIOL treats GALLSTONES,92,42,,101,50,treats,0.971285862357264,907935-FS1-2,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL,RO-may_treat
503223375,7/15/2014 11:04:22,,1323512190,7/15/2014 11:03:56,prodege,0.6528,28039757,GBR,L8,Southport,109.155.158.54,URSODIOL treats GALLSTONES,92,42,,101,50,treats,0.971285862357264,907935-FS1-2,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL,RO-may_treat
503223375,7/15/2014 11:20:04,,1323523977,7/15/2014 11:19:39,instagc,0.7264,24252915,GBR,B7,Bristol,77.98.139.82,URSODIOL treats GALLSTONES,92,42,,101,50,treats,0.971285862357264,907935-FS1-2,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL,RO-may_treat
503223375,7/15/2014 11:20:52,,1323524361,7/15/2014 11:20:25,instagc,0.8431,13763729,USA,"","",75.182.89.225,URSODIOL treats GALLSTONES,92,42,,101,50,treats,0.971285862357264,907935-FS1-2,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL,RO-may_treat
503223375,7/15/2014 13:05:28,,1323571780,7/15/2014 13:05:20,clixsense,0.601,20614047,USA,ID,Priest River,174.32.160.124,URSODIOL treats GALLSTONES,92,42,,101,50,treats,0.971285862357264,907935-FS1-2,"Successful dissolution of gallstones with URSODIOL occurs rarely in patients with calcified GALLSTONES prior to treatment, those who develop stone calcification or gallbladder nonvisualization during treatment, and those with gallstones &gt;20 mm in greatest diameter.",GALLSTONES,URSODIOL,RO-may_treat
503223376,7/15/2014 10:08:30,,1323475791,7/15/2014 10:08:04,clixsense,0.875,15189335,GBR,E4,Colchester,5.67.141.89,TACHYCARDIA causes SUSTAINED VENTRICULAR TACHYCARDIA,208,248,,218,281,causes,0.447213595499958,904545-FS1-4,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA,RO-has_definitional_manifestation
503223376,7/15/2014 11:52:08,,1323542654,7/15/2014 11:51:48,neodev,0.6736,24578640,USA,IL,Chicago,65.60.20.66,TACHYCARDIA causes SUSTAINED VENTRICULAR TACHYCARDIA,208,248,,218,281,causes,0.447213595499958,904545-FS1-4,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA,RO-has_definitional_manifestation
503223376,7/15/2014 12:12:36,,1323551381,7/15/2014 12:12:15,paiddailysurveys,0.6127,11786001,USA,NC,Charlotte,71.28.89.238,TACHYCARDIA causes SUSTAINED VENTRICULAR TACHYCARDIA,208,248,,218,281,causes,0.447213595499958,904545-FS1-4,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA,RO-has_definitional_manifestation
503223376,7/15/2014 13:50:36,,1323586885,7/15/2014 13:49:58,neodev,0.4671,18339121,USA,SC,Sumter,173.93.188.194,TACHYCARDIA causes SUSTAINED VENTRICULAR TACHYCARDIA,208,248,,218,281,causes,0.447213595499958,904545-FS1-4,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA,RO-has_definitional_manifestation
503223376,7/15/2014 14:19:40,,1323595117,7/15/2014 14:19:09,instagc,0.6554,19636746,USA,NY,Andover,192.182.216.225,no_relation,208,248,,218,281,causes,0.447213595499958,904545-FS1-4,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA,RO-has_definitional_manifestation
503223376,7/15/2014 16:46:08,,1323696628,7/15/2014 16:46:02,prodege,0.474,2143114,CAN,BC,Vancouver,24.84.160.12,TACHYCARDIA causes SUSTAINED VENTRICULAR TACHYCARDIA,208,248,,218,281,causes,0.447213595499958,904545-FS1-4,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA,RO-has_definitional_manifestation
503223376,7/15/2014 16:51:16,,1323702177,7/15/2014 16:50:51,prodege,0.5758,23541832,USA,AZ,Tempe,149.169.145.144,no_relation,208,248,,218,281,causes,0.447213595499958,904545-FS1-4,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA,RO-has_definitional_manifestation
503223377,7/15/2014 10:27:06,,1323487196,7/15/2014 10:26:36,vivatic,0.8056,25451531,GBR,"","",83.67.28.193,no_relation,91,32,,101,44,treats,0.935414346693485,907851-FS1-2,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE,RO-may_treat
503223377,7/15/2014 12:22:34,,1323555299,7/15/2014 12:21:40,paiddailysurveys,0.6127,11786001,USA,NC,Charlotte,71.28.89.238,CLOMIPRAMINE treats PAIN RELIEF,91,32,,101,44,treats,0.935414346693485,907851-FS1-2,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE,RO-may_treat
503223377,7/15/2014 14:18:18,,1323594790,7/15/2014 14:17:45,instagc,0.6554,19636746,USA,NY,Andover,192.182.216.225,no_relation,91,32,,101,44,treats,0.935414346693485,907851-FS1-2,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE,RO-may_treat
503223377,7/15/2014 14:27:21,,1323597371,7/15/2014 14:26:59,elite,0.6381,28276268,USA,FL,Boynton Beach,99.114.225.45,CLOMIPRAMINE treats PAIN RELIEF,91,32,,101,44,treats,0.935414346693485,907851-FS1-2,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE,RO-may_treat
503223377,7/15/2014 14:32:35,,1323599001,7/15/2014 14:32:30,neodev,0.3913,25224036,CAN,ON,Sudbury,67.204.218.187,PAIN RELIEF treats CLOMIPRAMINE,91,32,,101,44,treats,0.935414346693485,907851-FS1-2,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE,RO-may_treat
503223377,7/15/2014 15:31:21,,1323627456,7/15/2014 15:31:06,tremorgames,0.5508,24449707,CAN,QC,Laval,96.21.249.72,CLOMIPRAMINE treats PAIN RELIEF,91,32,,101,44,treats,0.935414346693485,907851-FS1-2,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE,RO-may_treat
503223377,7/15/2014 15:49:07,,1323640572,7/15/2014 15:48:52,clixsense,0.6403,7265596,USA,IA,Neola,199.120.116.136,CLOMIPRAMINE treats PAIN RELIEF,91,32,,101,44,treats,0.935414346693485,907851-FS1-2,1 trial comparing tramadol with CLOMIPRAMINE with or without levomepromazine showed better PAIN RELIEF with tramadol but no difference in pain intensity between groups.,PAIN RELIEF,CLOMIPRAMINE,RO-may_treat
503223378,7/15/2014 10:51:38,,1323504285,7/15/2014 10:51:24,clixsense,0.8486,27793793,GBR,C5,Chester,151.230.27.155,no_relation,37,108,,90,120,is location of,0.353553390593274,902461-FS1-9,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503223378,7/15/2014 12:57:58,,1323568820,7/15/2014 12:57:35,elite,0.8028,28503042,USA,NJ,Woodbridge,54.191.150.115,no_relation,37,108,,90,120,is location of,0.353553390593274,902461-FS1-9,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503223378,7/15/2014 13:04:24,,1323571478,7/15/2014 13:04:16,clixsense,0.601,20614047,USA,ID,Priest River,174.32.160.124,CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS is location of OSTEOPOROSIS,37,108,,90,120,is location of,0.353553390593274,902461-FS1-9,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503223378,7/15/2014 15:51:26,,1323642418,7/15/2014 15:51:01,neodev,0.624,14861092,GBR,I2,Manchester,90.194.137.76,CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS is location of OSTEOPOROSIS,37,108,,90,120,is location of,0.353553390593274,902461-FS1-9,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503223378,7/15/2014 16:45:49,,1323696291,7/15/2014 16:45:39,prodege,0.474,2143114,CAN,BC,Vancouver,24.84.160.12,CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS is location of OSTEOPOROSIS,37,108,,90,120,is location of,0.353553390593274,902461-FS1-9,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503223378,7/15/2014 16:50:33,,1323701457,7/15/2014 16:50:09,prodege,0.5758,23541832,USA,AZ,Tempe,149.169.145.144,no_relation,37,108,,90,120,is location of,0.353553390593274,902461-FS1-9,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503223378,7/15/2014 16:54:14,,1323705321,7/15/2014 16:53:40,prodege,0.5952,9525153,CAN,ON,Toronto,65.95.187.40,CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS is location of OSTEOPOROSIS,37,108,,90,120,is location of,0.353553390593274,902461-FS1-9,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503223379,7/15/2014 10:27:32,,1323487472,7/15/2014 10:27:13,clixsense,0.8472,19803139,NLD,06,Veldhoven,212.61.84.196,IVERMECTIN treats ONCHOCERCIASIS,69,14,,82,24,treats,1,907881-FS1-2,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN,RO-may_treat
503223379,7/15/2014 10:31:36,,1323490265,7/15/2014 10:31:28,clixsense,0.6875,19162475,GBR,M3,Frome,82.33.126.30,ONCHOCERCIASIS treats IVERMECTIN,69,14,,82,24,treats,1,907881-FS1-2,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN,RO-may_treat
503223379,7/15/2014 10:50:57,,1323503714,7/15/2014 10:50:01,rewardsspot,0.6319,17763704,USA,VA,Manassas,198.7.62.204,IVERMECTIN treats ONCHOCERCIASIS,69,14,,82,24,treats,1,907881-FS1-2,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN,RO-may_treat
503223379,7/15/2014 10:52:01,,1323504531,7/15/2014 10:51:52,clixsense,0.8486,27793793,GBR,C5,Chester,151.230.27.155,IVERMECTIN treats ONCHOCERCIASIS,69,14,,82,24,treats,1,907881-FS1-2,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN,RO-may_treat
503223379,7/15/2014 11:05:10,,1323512950,7/15/2014 11:04:45,prodege,0.6528,28039757,GBR,L8,Southport,109.155.158.54,IVERMECTIN treats ONCHOCERCIASIS,69,14,,82,24,treats,1,907881-FS1-2,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN,RO-may_treat
503223379,7/15/2014 11:50:11,,1323541182,7/15/2014 11:49:45,neodev,0.6637,21515166,NLD,11,Nootdorp,83.86.58.179,IVERMECTIN treats ONCHOCERCIASIS,69,14,,82,24,treats,1,907881-FS1-2,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN,RO-may_treat
503223379,7/15/2014 14:10:54,,1323592694,7/15/2014 14:10:33,neodev,0.4365,28336203,USA,PA,Harrisburg,50.149.53.150,IVERMECTIN treats ONCHOCERCIASIS,69,14,,82,24,treats,1,907881-FS1-2,Comparison of IVERMECTIN and diethylcarbamazine for the treatment of ONCHOCERCIASIS,ONCHOCERCIASIS,IVERMECTIN,RO-may_treat
503223380,7/15/2014 12:37:39,,1323560878,7/15/2014 12:37:00,prodege,0.5236,1852770,USA,TX,Abilene,76.198.102.54,no_relation,248,273,,263,299,causes,0.617213399848368,901857-FS1-4,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,RO-disease_has_finding
503223380,7/15/2014 12:58:18,,1323568969,7/15/2014 12:58:00,elite,0.8028,28503042,USA,NJ,Woodbridge,54.191.150.115,no_relation,248,273,,263,299,causes,0.617213399848368,901857-FS1-4,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,RO-disease_has_finding
503223380,7/15/2014 13:10:33,,1323573699,7/15/2014 13:10:06,neodev,0.4365,28336203,USA,PA,Harrisburg,50.149.53.150,SQUAMOUS CARCINOMA IN SITU causes SEVERE DYSPLASIA,248,273,,263,299,causes,0.617213399848368,901857-FS1-4,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,RO-disease_has_finding
503223380,7/15/2014 13:49:47,,1323586730,7/15/2014 13:49:18,neodev,0.4671,18339121,USA,SC,Sumter,173.93.188.194,SEVERE DYSPLASIA causes SQUAMOUS CARCINOMA IN SITU,248,273,,263,299,causes,0.617213399848368,901857-FS1-4,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,RO-disease_has_finding
503223380,7/15/2014 15:20:35,,1323619847,7/15/2014 15:20:09,prodege,0.5683,7899370,USA,MI,Bay City,71.13.81.162,no_relation,248,273,,263,299,causes,0.617213399848368,901857-FS1-4,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,RO-disease_has_finding
503223380,7/15/2014 15:30:55,,1323627127,7/15/2014 15:30:44,tremorgames,0.5508,24449707,CAN,QC,Laval,96.21.249.72,no_relation,248,273,,263,299,causes,0.617213399848368,901857-FS1-4,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,RO-disease_has_finding
503223380,7/15/2014 16:25:57,,1323672418,7/15/2014 16:25:48,clixsense,0.475,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,248,273,,263,299,causes,0.617213399848368,901857-FS1-4,"Follow up was available on 63 cases: Seven had negative follow up smears for at least 2 years, 15 had negative biopsies, seven had endocervical polyps, two had endometrial hyperplasia, eight had mild dysplasia, five had moderate dysplasia, six had SEVERE DYSPLASIA six had SQUAMOUS CARCINOMA IN SITU five had adenocarcinoma in situ, and two had invasive adenocarcinoma.",SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,RO-disease_has_finding
503223381,7/15/2014 10:51:23,,1323504080,7/15/2014 10:51:12,clixsense,0.8486,27793793,GBR,C5,Chester,151.230.27.155,CARCINOMA IN SITU causes SEVERE DYSPLASIA,69,90,,84,107,causes,0.471404520791032,901966-FS1-4,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU,RO-disease_has_finding
503223381,7/15/2014 11:05:10,,1323512949,7/15/2014 11:04:45,prodege,0.6528,28039757,GBR,L8,Southport,109.155.158.54,no_relation,69,90,,84,107,causes,0.471404520791032,901966-FS1-4,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU,RO-disease_has_finding
503223381,7/15/2014 11:13:48,,1323519975,7/15/2014 11:13:11,prodege,0.7681,11864493,GBR,Z4,Wrexham,212.219.196.69,no_relation,69,90,,84,107,causes,0.471404520791032,901966-FS1-4,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU,RO-disease_has_finding
503223381,7/15/2014 11:14:09,,1323520167,7/15/2014 11:13:33,prodege,0.6058,27934334,GBR,B9,High Wycombe,86.166.72.139,no_relation,69,90,,84,107,causes,0.471404520791032,901966-FS1-4,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU,RO-disease_has_finding
503223381,7/15/2014 11:38:48,,1323534615,7/15/2014 11:38:26,clixsense,0.5726,23233834,GBR,N6,Sunderland,86.17.58.181,SEVERE DYSPLASIA causes CARCINOMA IN SITU,69,90,,84,107,causes,0.471404520791032,901966-FS1-4,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU,RO-disease_has_finding
503223381,7/15/2014 13:32:04,,1323580873,7/15/2014 13:31:06,instagc,0.5063,23149109,USA,NC,Cary,24.206.38.18,SEVERE DYSPLASIA causes CARCINOMA IN SITU,69,90,,84,107,causes,0.471404520791032,901966-FS1-4,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU,RO-disease_has_finding
503223381,7/15/2014 13:49:10,,1323586557,7/15/2014 13:48:14,neodev,0.4671,18339121,USA,SC,Sumter,173.93.188.194,no_relation,69,90,,84,107,causes,0.471404520791032,901966-FS1-4,Squamous intraepithelial neoplasia was present in 99 (43%) of these  SEVERE DYSPLASIA and CARCINOMA IN SITU comprised over half of the cases.,SEVERE DYSPLASIA,CARCINOMA IN SITU,RO-disease_has_finding
503223382,7/15/2014 10:06:50,,1323474878,7/15/2014 10:06:29,clixsense,0.875,15189335,GBR,E4,Colchester,5.67.141.89,CALCIFICATION causes PILOMATRICOMA,137,58,,149,71,causes,0.589767824619588,902676-FS1-4,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA,RO-disease_may_have_finding
503223382,7/15/2014 10:29:24,,1323488764,7/15/2014 10:28:55,clixsense,0.8472,19803139,NLD,06,Veldhoven,212.61.84.196,PILOMATRICOMA causes CALCIFICATION,137,58,,149,71,causes,0.589767824619588,902676-FS1-4,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA,RO-disease_may_have_finding
503223382,7/15/2014 11:15:02,,1323520691,7/15/2014 11:14:30,clixsense,0.8306,27871219,NLD,07,Amsterdam,87.210.207.223,CALCIFICATION causes PILOMATRICOMA,137,58,,149,71,causes,0.589767824619588,902676-FS1-4,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA,RO-disease_may_have_finding
503223382,7/15/2014 11:26:51,,1323527620,7/15/2014 11:26:32,instagc,0.7611,28301350,GBR,K4,Plymouth,92.28.215.248,no_relation,137,58,,149,71,causes,0.589767824619588,902676-FS1-4,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA,RO-disease_may_have_finding
503223382,7/15/2014 11:39:13,,1323534824,7/15/2014 11:38:49,clixsense,0.5726,23233834,GBR,N6,Sunderland,86.17.58.181,CALCIFICATION causes PILOMATRICOMA,137,58,,149,71,causes,0.589767824619588,902676-FS1-4,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA,RO-disease_may_have_finding
503223382,7/15/2014 12:04:58,,1323548696,7/15/2014 12:04:31,prodege,0.35,7664351,USA,NY,Cicero,74.111.0.21,no_relation,137,58,,149,71,causes,0.589767824619588,902676-FS1-4,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA,RO-disease_may_have_finding
503223382,7/15/2014 12:12:36,,1323551380,7/15/2014 12:12:15,paiddailysurveys,0.6127,11786001,USA,NC,Charlotte,71.28.89.238,PILOMATRICOMA causes CALCIFICATION,137,58,,149,71,causes,0.589767824619588,902676-FS1-4,Amyloid deposition was encountered in 10 of 16 samples of PILOMATRICOMA indicating that the deposition of amyloid is nearly as common as CALCIFICATION in pilomatricoma.,CALCIFICATION,PILOMATRICOMA,RO-disease_may_have_finding
503223383,7/15/2014 11:18:32,,1323523005,7/15/2014 11:18:02,instagc,0.7264,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,153,68,,193,113,treats,0.371390676354104,903512-FS1-2,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223383,7/15/2014 11:21:16,,1323524624,7/15/2014 11:20:53,instagc,0.8431,13763729,USA,"","",75.182.89.225,no_relation,153,68,,193,113,treats,0.371390676354104,903512-FS1-2,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223383,7/15/2014 11:27:19,,1323527948,7/15/2014 11:26:47,elite,0.7417,28397222,GBR,Y4,Usk,31.50.223.75,no_relation,153,68,,193,113,treats,0.371390676354104,903512-FS1-2,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223383,7/15/2014 11:49:44,,1323540810,7/15/2014 11:49:18,neodev,0.6637,21515166,NLD,11,Nootdorp,83.86.58.179,ADMINISTRATION OF THE DRUG AFTER THE TEST treats AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,153,68,,193,113,treats,0.371390676354104,903512-FS1-2,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223383,7/15/2014 11:52:33,,1323543001,7/15/2014 11:52:10,neodev,0.6736,24578640,USA,IL,Chicago,65.60.20.66,ADMINISTRATION OF THE DRUG AFTER THE TEST treats AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,153,68,,193,113,treats,0.371390676354104,903512-FS1-2,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223383,7/15/2014 12:39:40,,1323561656,7/15/2014 12:39:23,instagc,0.7472,18960682,GBR,"","",86.29.147.112,no_relation,153,68,,193,113,treats,0.371390676354104,903512-FS1-2,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223383,7/15/2014 13:29:38,,1323580207,7/15/2014 13:28:59,instagc,0.5063,23149109,USA,NC,Cary,24.206.38.18,ADMINISTRATION OF THE DRUG AFTER THE TEST treats AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,153,68,,193,113,treats,0.371390676354104,903512-FS1-2,When tolerant rats are later allowed to drink milk from a bottle in AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN when drug exposure is held constant by ADMINISTRATION OF THE DRUG AFTER THE TEST.,ADMINISTRATION OF THE DRUG AFTER THE TEST,AN UNINTOXICATED STATE TOLERANCE IS LOST EVEN,RO-has_causative_agent
503223384,7/15/2014 10:06:28,,1323474659,7/15/2014 10:06:05,clixsense,0.875,15189335,GBR,E4,Colchester,5.67.141.89,SKIN is location of DERMATITIS,61,0,,64,10,is location of,0.929981109950554,905059-FS1-9,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS,RO-has_finding_site
503223384,7/15/2014 11:14:47,,1323520521,7/15/2014 11:14:19,prodege,0.7681,11864493,GBR,Z4,Wrexham,212.219.196.69,SKIN is location of DERMATITIS,61,0,,64,10,is location of,0.929981109950554,905059-FS1-9,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS,RO-has_finding_site
503223384,7/15/2014 11:37:55,,1323534064,7/15/2014 11:37:25,clixsense,0.5726,23233834,GBR,N6,Sunderland,86.17.58.181,SKIN is location of DERMATITIS,61,0,,64,10,is location of,0.929981109950554,905059-FS1-9,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS,RO-has_finding_site
503223384,7/15/2014 11:52:33,,1323543003,7/15/2014 11:52:10,neodev,0.6736,24578640,USA,IL,Chicago,65.60.20.66,DERMATITIS is location of SKIN,61,0,,64,10,is location of,0.929981109950554,905059-FS1-9,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS,RO-has_finding_site
503223384,7/15/2014 12:39:57,,1323561737,7/15/2014 12:39:41,instagc,0.7472,18960682,GBR,"","",86.29.147.112,SKIN is location of DERMATITIS,61,0,,64,10,is location of,0.929981109950554,905059-FS1-9,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS,RO-has_finding_site
503223384,7/15/2014 12:57:34,,1323568642,7/15/2014 12:57:19,elite,0.8028,28503042,USA,NJ,Woodbridge,54.191.150.115,SKIN is location of DERMATITIS,61,0,,64,10,is location of,0.929981109950554,905059-FS1-9,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS,RO-has_finding_site
503223384,7/15/2014 13:48:07,,1323586308,7/15/2014 13:47:31,prodege,0.6706,13795372,CAN,NS,Dartmouth,142.68.155.182,SKIN is location of DERMATITIS,61,0,,64,10,is location of,0.929981109950554,905059-FS1-9,"DERMATITIS resulting from irritation or sensitization of the SKIN by urushiol, the toxic resin of the Rhus (Toxicodendron) family of plants.",SKIN,DERMATITIS,RO-has_finding_site
503223385,7/15/2014 10:20:29,,1323483163,7/15/2014 10:19:56,gifthulk,0.9583,22144176,GBR,U8,Edinburgh,129.215.149.99,no_relation,87,171,,112,188,causes,0.4,901731-FS1-4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223385,7/15/2014 10:28:25,,1323488192,7/15/2014 10:27:44,vivatic,0.8056,25451531,GBR,"","",83.67.28.193,no_relation,87,171,,112,188,causes,0.4,901731-FS1-4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223385,7/15/2014 11:28:07,,1323528459,7/15/2014 11:27:48,instagc,0.7611,28301350,GBR,K4,Plymouth,92.28.215.248,no_relation,87,171,,112,188,causes,0.4,901731-FS1-4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223385,7/15/2014 11:39:13,,1323534825,7/15/2014 11:38:49,clixsense,0.5726,23233834,GBR,N6,Sunderland,86.17.58.181,FOLLICULAR DIFFERENTIATION causes TRICHOFOLLICULOMA,87,171,,112,188,causes,0.4,901731-FS1-4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223385,7/15/2014 13:28:57,,1323580024,7/15/2014 13:28:25,instagc,0.5063,23149109,USA,NC,Cary,24.206.38.18,TRICHOFOLLICULOMA causes FOLLICULAR DIFFERENTIATION,87,171,,112,188,causes,0.4,901731-FS1-4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223385,7/15/2014 13:52:40,,1323587499,7/15/2014 13:51:55,neodev,0.4671,18339121,USA,SC,Sumter,173.93.188.194,TRICHOFOLLICULOMA causes FOLLICULAR DIFFERENTIATION,87,171,,112,188,causes,0.4,901731-FS1-4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223385,7/15/2014 14:28:46,,1323597870,7/15/2014 14:28:26,elite,0.6381,28276268,USA,FL,Boynton Beach,99.114.225.45,FOLLICULAR DIFFERENTIATION causes TRICHOFOLLICULOMA,87,171,,112,188,causes,0.4,901731-FS1-4,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223386,7/15/2014 11:12:25,,1323519098,7/15/2014 11:11:59,prodege,0.7681,11864493,GBR,Z4,Wrexham,212.219.196.69,no_relation,66,103,,70,111,causes,0.794719414239026,902366-FS1-4,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY,RO-disease_has_primary_anatomic_site
503223386,7/15/2014 11:14:29,,1323520381,7/15/2014 11:13:54,clixsense,0.8306,27871219,NLD,07,Amsterdam,87.210.207.223,no_relation,66,103,,70,111,causes,0.794719414239026,902366-FS1-4,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY,RO-disease_has_primary_anatomic_site
503223386,7/15/2014 12:23:52,,1323555746,7/15/2014 12:23:23,paiddailysurveys,0.6127,11786001,USA,NC,Charlotte,71.28.89.238,BRAIN causes EPILEPSY,66,103,,70,111,causes,0.794719414239026,902366-FS1-4,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY,RO-disease_has_primary_anatomic_site
503223386,7/15/2014 15:52:37,,1323643304,7/15/2014 15:52:09,neodev,0.624,14861092,GBR,I2,Manchester,90.194.137.76,no_relation,66,103,,70,111,causes,0.794719414239026,902366-FS1-4,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY,RO-disease_has_primary_anatomic_site
503223386,7/15/2014 16:46:01,,1323696495,7/15/2014 16:45:51,prodege,0.474,2143114,CAN,BC,Vancouver,24.84.160.12,BRAIN causes EPILEPSY,66,103,,70,111,causes,0.794719414239026,902366-FS1-4,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY,RO-disease_has_primary_anatomic_site
503223386,7/15/2014 16:47:00,,1323697670,7/15/2014 16:46:14,clixsense,0.881,6455807,CAN,BC,Victoria,96.54.172.117,no_relation,66,103,,70,111,causes,0.794719414239026,902366-FS1-4,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY,RO-disease_has_primary_anatomic_site
503223386,7/15/2014 16:50:50,,1323701800,7/15/2014 16:50:33,prodege,0.5758,23541832,USA,AZ,Tempe,149.169.145.144,no_relation,66,103,,70,111,causes,0.794719414239026,902366-FS1-4,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY,RO-disease_has_primary_anatomic_site
503223387,7/15/2014 10:08:03,,1323475548,7/15/2014 10:07:28,clixsense,0.875,15189335,GBR,E4,Colchester,5.67.141.89,TRICHOFOLLICULOMA diagnosed by FOLLICULAR DIFFERENTIATION,87,171,,112,188,diagnosed by,0.4,901731-FS1-13,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223387,7/15/2014 10:18:32,,1323481796,7/15/2014 10:18:15,gifthulk,0.9583,22144176,GBR,U8,Edinburgh,129.215.149.99,no_relation,87,171,,112,188,diagnosed by,0.4,901731-FS1-13,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223387,7/15/2014 10:51:51,,1323504421,7/15/2014 10:51:39,clixsense,0.8486,27793793,GBR,C5,Chester,151.230.27.155,no_relation,87,171,,112,188,diagnosed by,0.4,901731-FS1-13,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223387,7/15/2014 11:03:03,,1323511248,7/15/2014 11:02:32,prodege,0.6528,28039757,GBR,L8,Southport,109.155.158.54,no_relation,87,171,,112,188,diagnosed by,0.4,901731-FS1-13,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223387,7/15/2014 11:13:53,,1323520045,7/15/2014 11:13:23,clixsense,0.8306,27871219,NLD,07,Amsterdam,87.210.207.223,no_relation,87,171,,112,188,diagnosed by,0.4,901731-FS1-13,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223387,7/15/2014 12:57:17,,1323568524,7/15/2014 12:56:44,elite,0.8028,28503042,USA,NJ,Woodbridge,54.191.150.115,TRICHOFOLLICULOMA diagnosed by FOLLICULAR DIFFERENTIATION,87,171,,112,188,diagnosed by,0.4,901731-FS1-13,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223387,7/15/2014 13:05:01,,1323571640,7/15/2014 13:04:52,clixsense,0.601,20614047,USA,ID,Priest River,174.32.160.124,TRICHOFOLLICULOMA diagnosed by FOLLICULAR DIFFERENTIATION,87,171,,112,188,diagnosed by,0.4,901731-FS1-13,We report a nodular lesion that was identified histopathologically as a hamartoma with FOLLICULAR DIFFERENTIATION and that systematic serial sectioning showed not to be a TRICHOFOLLICULOMA,FOLLICULAR DIFFERENTIATION,TRICHOFOLLICULOMA,RO-disease_has_finding
503223388,7/15/2014 10:22:46,,1323484685,7/15/2014 10:22:17,rewardsspot,0.8889,24482174,GBR,H9,London,46.23.68.180,COMPLICATION OF PREGNANCY causes PREECLAMPSIA,24,0,,48,12,causes,0.549442255794756,901762-FS1-4,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA,RO-disease_has_finding
503223388,7/15/2014 10:27:06,,1323487195,7/15/2014 10:26:36,vivatic,0.8056,25451531,GBR,"","",83.67.28.193,PREECLAMPSIA causes COMPLICATION OF PREGNANCY,24,0,,48,12,causes,0.549442255794756,901762-FS1-4,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA,RO-disease_has_finding
503223388,7/15/2014 10:28:13,,1323488039,7/15/2014 10:27:54,clixsense,0.8472,19803139,NLD,06,Veldhoven,212.61.84.196,PREECLAMPSIA causes COMPLICATION OF PREGNANCY,24,0,,48,12,causes,0.549442255794756,901762-FS1-4,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA,RO-disease_has_finding
503223388,7/15/2014 10:30:49,,1323489707,7/15/2014 10:30:36,clixsense,0.6875,19162475,GBR,M3,Frome,82.33.126.30,no_relation,24,0,,48,12,causes,0.549442255794756,901762-FS1-4,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA,RO-disease_has_finding
503223388,7/15/2014 10:51:38,,1323504288,7/15/2014 10:51:24,clixsense,0.8486,27793793,GBR,C5,Chester,151.230.27.155,PREECLAMPSIA causes COMPLICATION OF PREGNANCY,24,0,,48,12,causes,0.549442255794756,901762-FS1-4,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA,RO-disease_has_finding
503223388,7/15/2014 11:52:04,,1323542600,7/15/2014 11:51:08,instagc,0.4583,21551272,GBR,Q3,Wolverhampton,2.103.57.104,PREECLAMPSIA causes COMPLICATION OF PREGNANCY,24,0,,48,12,causes,0.549442255794756,901762-FS1-4,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA,RO-disease_has_finding
503223388,7/15/2014 13:30:01,,1323580300,7/15/2014 13:29:39,instagc,0.5063,23149109,USA,NC,Cary,24.206.38.18,PREECLAMPSIA causes COMPLICATION OF PREGNANCY,24,0,,48,12,causes,0.549442255794756,901762-FS1-4,PREECLAMPSIA is a major COMPLICATION OF PREGNANCY and a predictor of future chronic disease.,COMPLICATION OF PREGNANCY,PREECLAMPSIA,RO-disease_has_finding
503223389,7/15/2014 10:31:07,,1323489942,7/15/2014 10:30:59,clixsense,0.6875,19162475,GBR,M3,Frome,82.33.126.30,NICOTINE causes DEPENDENT SMOKERS,204,151,,211,168,causes,0.884651736929383,903754-FS1-4,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS,RO-has_causative_agent
503223389,7/15/2014 11:19:38,,1323523697,7/15/2014 11:19:03,instagc,0.7264,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,204,151,,211,168,causes,0.884651736929383,903754-FS1-4,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS,RO-has_causative_agent
503223389,7/15/2014 12:57:34,,1323568640,7/15/2014 12:57:19,elite,0.8028,28503042,USA,NJ,Woodbridge,54.191.150.115,NICOTINE causes DEPENDENT SMOKERS,204,151,,211,168,causes,0.884651736929383,903754-FS1-4,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS,RO-has_causative_agent
503223389,7/15/2014 13:11:59,,1323574235,7/15/2014 13:11:44,neodev,0.4365,28336203,USA,PA,Harrisburg,50.149.53.150,NICOTINE causes DEPENDENT SMOKERS,204,151,,211,168,causes,0.884651736929383,903754-FS1-4,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS,RO-has_causative_agent
503223389,7/15/2014 15:48:36,,1323640238,7/15/2014 15:48:14,clixsense,0.6403,7265596,USA,IA,Neola,199.120.116.136,NICOTINE causes DEPENDENT SMOKERS,204,151,,211,168,causes,0.884651736929383,903754-FS1-4,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS,RO-has_causative_agent
503223389,7/15/2014 16:24:47,,1323671020,7/15/2014 16:24:00,clixsense,0.475,16827630,GBR,A7,Birmingham,86.146.169.103,NICOTINE causes DEPENDENT SMOKERS,204,151,,211,168,causes,0.884651736929383,903754-FS1-4,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS,RO-has_causative_agent
503223389,7/15/2014 16:55:59,,1323707304,7/15/2014 16:55:42,prodege,0.5952,9525153,CAN,ON,Toronto,65.95.187.40,NICOTINE causes DEPENDENT SMOKERS,204,151,,211,168,causes,0.884651736929383,903754-FS1-4,"Contrary to our previous findings that cimetidine decreased the total body clearance of nicotine by 30% in a population of non smokers, in the heavily DEPENDENT SMOKERS cimetidine did not appear to alter NICOTINE elimination.",NICOTINE,DEPENDENT SMOKERS,RO-has_causative_agent
503223390,7/15/2014 10:24:47,,1323485717,7/15/2014 10:24:06,rewardsspot,0.8889,24482174,GBR,H9,London,46.23.68.180,ISCHEMIA diagnosed by RAT FOUR VESSEL OCCLUSION MODEL,143,185,,173,193,diagnosed by,0.927172649945531,905062-FS1-13,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA,RO-has_finding_site
503223390,7/15/2014 11:12:47,,1323519307,7/15/2014 11:12:01,prodege,0.6058,27934334,GBR,B9,High Wycombe,86.166.72.139,no_relation,143,185,,173,193,diagnosed by,0.927172649945531,905062-FS1-13,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA,RO-has_finding_site
503223390,7/15/2014 11:15:02,,1323520687,7/15/2014 11:14:30,clixsense,0.8306,27871219,NLD,07,Amsterdam,87.210.207.223,ISCHEMIA diagnosed by RAT FOUR VESSEL OCCLUSION MODEL,143,185,,173,193,diagnosed by,0.927172649945531,905062-FS1-13,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA,RO-has_finding_site
503223390,7/15/2014 11:19:38,,1323523699,7/15/2014 11:19:03,instagc,0.7264,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,143,185,,173,193,diagnosed by,0.927172649945531,905062-FS1-13,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA,RO-has_finding_site
503223390,7/15/2014 11:23:37,,1323525847,7/15/2014 11:23:16,prodege,0.7792,15439740,AUS,02,Jannali,27.96.208.89,no_relation,143,185,,173,193,diagnosed by,0.927172649945531,905062-FS1-13,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA,RO-has_finding_site
503223390,7/15/2014 11:27:31,,1323528065,7/15/2014 11:27:07,instagc,0.7611,28301350,GBR,K4,Plymouth,92.28.215.248,ISCHEMIA diagnosed by RAT FOUR VESSEL OCCLUSION MODEL,143,185,,173,193,diagnosed by,0.927172649945531,905062-FS1-13,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA,RO-has_finding_site
503223390,7/15/2014 15:53:00,,1323643544,7/15/2014 15:52:38,neodev,0.624,14861092,GBR,I2,Manchester,90.194.137.76,no_relation,143,185,,173,193,diagnosed by,0.927172649945531,905062-FS1-13,The effect of repeated transient global ischemia and microdialysis on changes in aminergic neurotransmitter release was investigated using the RAT FOUR VESSEL OCCLUSION MODEL of global ISCHEMIA,RAT FOUR VESSEL OCCLUSION MODEL,ISCHEMIA,RO-has_finding_site
503223391,7/15/2014 11:03:32,,1323511601,7/15/2014 11:03:04,prodege,0.6528,28039757,GBR,L8,Southport,109.155.158.54,no_relation,105,173,,120,186,treats,0.964901281354015,903564-FS1-2,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER,RO-has_causative_agent
503223391,7/15/2014 11:14:18,,1323520251,7/15/2014 11:13:48,prodege,0.7681,11864493,GBR,Z4,Wrexham,212.219.196.69,no_relation,105,173,,120,186,treats,0.964901281354015,903564-FS1-2,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER,RO-has_causative_agent
503223391,7/15/2014 11:37:24,,1323533714,7/15/2014 11:36:06,clixsense,0.5726,23233834,GBR,N6,Sunderland,86.17.58.181,SALMONELLA TYPHI treats TYPHOID FEVER,105,173,,120,186,treats,0.964901281354015,903564-FS1-2,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER,RO-has_causative_agent
503223391,7/15/2014 11:53:11,,1323543411,7/15/2014 11:52:58,neodev,0.6736,24578640,USA,IL,Chicago,65.60.20.66,SALMONELLA TYPHI treats TYPHOID FEVER,105,173,,120,186,treats,0.964901281354015,903564-FS1-2,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER,RO-has_causative_agent
503223391,7/15/2014 12:39:07,,1323561453,7/15/2014 12:38:53,instagc,0.7472,18960682,GBR,"","",86.29.147.112,SALMONELLA TYPHI treats TYPHOID FEVER,105,173,,120,186,treats,0.964901281354015,903564-FS1-2,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER,RO-has_causative_agent
503223391,7/15/2014 15:30:55,,1323627118,7/15/2014 15:30:44,tremorgames,0.5508,24449707,CAN,QC,Laval,96.21.249.72,SALMONELLA TYPHI treats TYPHOID FEVER,105,173,,120,186,treats,0.964901281354015,903564-FS1-2,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER,RO-has_causative_agent
503223391,7/15/2014 15:49:44,,1323641077,7/15/2014 15:49:34,clixsense,0.6403,7265596,USA,IA,Neola,199.120.116.136,SALMONELLA TYPHI treats TYPHOID FEVER,105,173,,120,186,treats,0.964901281354015,903564-FS1-2,The studies reported here were undertaken to assess the ability of the outer membrane proteins (OMPs) of SALMONELLA TYPHI to induce a humoral immune response in humans with TYPHOID FEVER,SALMONELLA TYPHI,TYPHOID FEVER,RO-has_causative_agent
503223392,7/15/2014 10:19:55,,1323482834,7/15/2014 10:19:17,gifthulk,0.9583,22144176,GBR,U8,Edinburgh,129.215.149.99,no_relation,157,140,,190,156,causes,0.338061701891407,902844-FS1-4,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
503223392,7/15/2014 11:21:16,,1323524621,7/15/2014 11:20:53,instagc,0.8431,13763729,USA,"","",75.182.89.225,no_relation,157,140,,190,156,causes,0.338061701891407,902844-FS1-4,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
503223392,7/15/2014 11:49:44,,1323540813,7/15/2014 11:49:18,neodev,0.6637,21515166,NLD,11,Nootdorp,83.86.58.179,PHEOCHROMOCYTOMA causes CARDIAC ISCHEMIA (ANGINAL HEADACHE,157,140,,190,156,causes,0.338061701891407,902844-FS1-4,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
503223392,7/15/2014 12:39:22,,1323561558,7/15/2014 12:39:08,instagc,0.7472,18960682,GBR,"","",86.29.147.112,no_relation,157,140,,190,156,causes,0.338061701891407,902844-FS1-4,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
503223392,7/15/2014 15:31:05,,1323627272,7/15/2014 15:30:56,tremorgames,0.5508,24449707,CAN,QC,Laval,96.21.249.72,PHEOCHROMOCYTOMA causes CARDIAC ISCHEMIA (ANGINAL HEADACHE,157,140,,190,156,causes,0.338061701891407,902844-FS1-4,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
503223392,7/15/2014 15:49:44,,1323641071,7/15/2014 15:49:34,clixsense,0.6403,7265596,USA,IA,Neola,199.120.116.136,PHEOCHROMOCYTOMA causes CARDIAC ISCHEMIA (ANGINAL HEADACHE,157,140,,190,156,causes,0.338061701891407,902844-FS1-4,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
503223392,7/15/2014 16:25:47,,1323672294,7/15/2014 16:25:37,clixsense,0.475,16827630,GBR,A7,Birmingham,86.146.169.103,PHEOCHROMOCYTOMA causes CARDIAC ISCHEMIA (ANGINAL HEADACHE,157,140,,190,156,causes,0.338061701891407,902844-FS1-4,"Depending on the clinical scenario and number of headaches, secondary causes may need to be excluded, such as SAH, sinusitis, brain tumors, PHEOCHROMOCYTOMA CARDIAC ISCHEMIA (ANGINAL HEADACHE and intracranial arterial dissection.",CARDIAC ISCHEMIA (ANGINAL HEADACHE,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
503223393,7/15/2014 10:08:18,,1323475656,7/15/2014 10:07:51,eup_slw,0.9167,20818028,GBR,A7,Birmingham,92.232.139.254,DRUGS causes ADVERSE DRUG REACTION,99,126,,103,147,causes,0.980196058819607,903731-FS1-4,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION,RO-has_causative_agent
503223393,7/15/2014 11:13:53,,1323520051,7/15/2014 11:13:23,clixsense,0.8306,27871219,NLD,07,Amsterdam,87.210.207.223,DRUGS causes ADVERSE DRUG REACTION,99,126,,103,147,causes,0.980196058819607,903731-FS1-4,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION,RO-has_causative_agent
503223393,7/15/2014 11:15:49,,1323521133,7/15/2014 11:14:57,prodege,0.6058,27934334,GBR,B9,High Wycombe,86.166.72.139,DRUGS causes ADVERSE DRUG REACTION,99,126,,103,147,causes,0.980196058819607,903731-FS1-4,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION,RO-has_causative_agent
503223393,7/15/2014 11:20:06,,1323523987,7/15/2014 11:19:46,instagc,0.8431,13763729,USA,"","",75.182.89.225,DRUGS causes ADVERSE DRUG REACTION,99,126,,103,147,causes,0.980196058819607,903731-FS1-4,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION,RO-has_causative_agent
503223393,7/15/2014 11:53:31,,1323543627,7/15/2014 11:53:13,neodev,0.6736,24578640,USA,IL,Chicago,65.60.20.66,DRUGS causes ADVERSE DRUG REACTION,99,126,,103,147,causes,0.980196058819607,903731-FS1-4,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION,RO-has_causative_agent
503223393,7/15/2014 16:58:59,,1323710891,7/15/2014 16:58:45,neodev,0.6701,18755947,GBR,H2,Accrington,80.47.185.52,DRUGS causes ADVERSE DRUG REACTION,99,126,,103,147,causes,0.980196058819607,903731-FS1-4,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION,RO-has_causative_agent
503223393,7/15/2014 17:06:39,,1323718643,7/15/2014 17:06:21,instagc,0.9286,19004168,GBR,H2,Accrington,80.47.185.52,DRUGS causes ADVERSE DRUG REACTION,99,126,,103,147,causes,0.980196058819607,903731-FS1-4,The objective of this study is to identify gender related differences in the types of symptoms and DRUGS reported to cause an ADVERSE DRUG REACTION,DRUGS,ADVERSE DRUG REACTION,RO-has_causative_agent
503223394,7/15/2014 10:07:49,,1323475415,7/15/2014 10:07:22,eup_slw,0.9167,20818028,GBR,A7,Birmingham,92.232.139.254,no_relation,107,66,,122,80,treats,0.925820099772551,903777-FS1-2,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE,RO-has_causative_agent
503223394,7/15/2014 10:25:31,,1323486250,7/15/2014 10:24:56,rewardsspot,0.8889,24482174,GBR,H9,London,46.23.68.180,GLUTEN FREE DIET treats CELIAC DISEASE,107,66,,122,80,treats,0.925820099772551,903777-FS1-2,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE,RO-has_causative_agent
503223394,7/15/2014 10:30:29,,1323489450,7/15/2014 10:29:47,vivatic,0.8056,25451531,GBR,"","",83.67.28.193,GLUTEN FREE DIET treats CELIAC DISEASE,107,66,,122,80,treats,0.925820099772551,903777-FS1-2,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE,RO-has_causative_agent
503223394,7/15/2014 11:13:32,,1323519749,7/15/2014 11:12:48,prodege,0.6058,27934334,GBR,B9,High Wycombe,86.166.72.139,GLUTEN FREE DIET treats CELIAC DISEASE,107,66,,122,80,treats,0.925820099772551,903777-FS1-2,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE,RO-has_causative_agent
503223394,7/15/2014 12:23:21,,1323555567,7/15/2014 12:22:36,paiddailysurveys,0.6127,11786001,USA,NC,Charlotte,71.28.89.238,GLUTEN FREE DIET treats CELIAC DISEASE,107,66,,122,80,treats,0.925820099772551,903777-FS1-2,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE,RO-has_causative_agent
503223394,7/15/2014 13:10:04,,1323573537,7/15/2014 13:09:33,neodev,0.4365,28336203,USA,PA,Harrisburg,50.149.53.150,no_relation,107,66,,122,80,treats,0.925820099772551,903777-FS1-2,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE,RO-has_causative_agent
503223394,7/15/2014 14:18:57,,1323594926,7/15/2014 14:18:21,instagc,0.6554,19636746,USA,NY,Andover,192.182.216.225,GLUTEN FREE DIET treats CELIAC DISEASE,107,66,,122,80,treats,0.925820099772551,903777-FS1-2,"In the past, oats were considered to be toxic to individuals with CELIAC DISEASE and were not allowed in a GLUTEN FREE DIET.",GLUTEN FREE DIET,CELIAC DISEASE,RO-has_causative_agent
503223395,7/15/2014 10:27:32,,1323487497,7/15/2014 10:27:13,clixsense,0.8472,19803139,NLD,06,Veldhoven,212.61.84.196,no_relation,88,11,,98,22,treats,0.997458699830735,907651-FS1-2,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE,RO-may_treat
503223395,7/15/2014 11:11:04,,1323518049,7/15/2014 11:10:08,elite,0.7417,28397222,GBR,Y4,Usk,31.50.223.75,EPINEPHRINE treats ANAPHYLAXIS,88,11,,98,22,treats,0.997458699830735,907651-FS1-2,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE,RO-may_treat
503223395,7/15/2014 11:25:54,,1323527111,7/15/2014 11:25:32,prodege,0.7792,15439740,AUS,02,Jannali,27.96.208.89,EPINEPHRINE treats ANAPHYLAXIS,88,11,,98,22,treats,0.997458699830735,907651-FS1-2,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE,RO-may_treat
503223395,7/15/2014 11:48:57,,1323540366,7/15/2014 11:48:30,neodev,0.6637,21515166,NLD,11,Nootdorp,83.86.58.179,EPINEPHRINE treats ANAPHYLAXIS,88,11,,98,22,treats,0.997458699830735,907651-FS1-2,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE,RO-may_treat
503223395,7/15/2014 11:52:08,,1323542656,7/15/2014 11:51:48,neodev,0.6736,24578640,USA,IL,Chicago,65.60.20.66,ANAPHYLAXIS treats EPINEPHRINE,88,11,,98,22,treats,0.997458699830735,907651-FS1-2,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE,RO-may_treat
503223395,7/15/2014 12:24:45,,1323556100,7/15/2014 12:23:54,paiddailysurveys,0.6127,11786001,USA,NC,Charlotte,71.28.89.238,EPINEPHRINE treats ANAPHYLAXIS,88,11,,98,22,treats,0.997458699830735,907651-FS1-2,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE,RO-may_treat
503223395,7/15/2014 13:28:57,,1323580027,7/15/2014 13:28:25,instagc,0.5063,23149109,USA,NC,Cary,24.206.38.18,EPINEPHRINE treats ANAPHYLAXIS,88,11,,98,22,treats,0.997458699830735,907651-FS1-2,"1 ,   108  EPINEPHRINE and other appropriate agents should be readily available in case ANAPHYLAXIS or other serious allergic reaction occurs.",ANAPHYLAXIS,EPINEPHRINE,RO-may_treat
503223396,7/15/2014 10:18:50,,1323481999,7/15/2014 10:18:33,gifthulk,0.9583,22144176,GBR,U8,Edinburgh,129.215.149.99,no_relation,0,47,,13,75,causes,0.995037190209989,906433-FS1-4,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY,RO-has_manifestation
503223396,7/15/2014 10:53:18,,1323505325,7/15/2014 10:52:46,rewardsspot,0.6319,17763704,USA,VA,Manassas,198.7.62.204,PRIMARY CARNITINE DEFICIENCY causes HYPERAMMONEMIA,0,47,,13,75,causes,0.995037190209989,906433-FS1-4,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY,RO-has_manifestation
503223396,7/15/2014 11:18:02,,1323522686,7/15/2014 11:17:33,instagc,0.7264,24252915,GBR,B7,Bristol,77.98.139.82,PRIMARY CARNITINE DEFICIENCY causes HYPERAMMONEMIA,0,47,,13,75,causes,0.995037190209989,906433-FS1-4,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY,RO-has_manifestation
503223396,7/15/2014 11:24:45,,1323526568,7/15/2014 11:24:27,prodege,0.7792,15439740,AUS,02,Jannali,27.96.208.89,PRIMARY CARNITINE DEFICIENCY causes HYPERAMMONEMIA,0,47,,13,75,causes,0.995037190209989,906433-FS1-4,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY,RO-has_manifestation
503223396,7/15/2014 11:27:06,,1323527793,7/15/2014 11:26:53,instagc,0.7611,28301350,GBR,K4,Plymouth,92.28.215.248,PRIMARY CARNITINE DEFICIENCY causes HYPERAMMONEMIA,0,47,,13,75,causes,0.995037190209989,906433-FS1-4,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY,RO-has_manifestation
503223396,7/15/2014 11:53:31,,1323543631,7/15/2014 11:53:13,neodev,0.6736,24578640,USA,IL,Chicago,65.60.20.66,PRIMARY CARNITINE DEFICIENCY causes HYPERAMMONEMIA,0,47,,13,75,causes,0.995037190209989,906433-FS1-4,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY,RO-has_manifestation
503223396,7/15/2014 14:33:03,,1323599186,7/15/2014 14:32:57,neodev,0.3913,25224036,CAN,ON,Sudbury,67.204.218.187,HYPERAMMONEMIA causes PRIMARY CARNITINE DEFICIENCY,0,47,,13,75,causes,0.995037190209989,906433-FS1-4,HYPERAMMONEMIA is one of the major symptoms of PRIMARY CARNITINE DEFICIENCY,HYPERAMMONEMIA,PRIMARY CARNITINE DEFICIENCY,RO-has_manifestation
503223397,7/15/2014 10:31:07,,1323489943,7/15/2014 10:30:59,clixsense,0.6875,19162475,GBR,M3,Frome,82.33.126.30,MENTAL RETARDATION causes X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS,177,75,,194,117,causes,0.589767824619588,906021-FS1-4,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS,RO-has_manifestation
503223397,7/15/2014 14:32:49,,1323599088,7/15/2014 14:32:43,neodev,0.3913,25224036,CAN,ON,Sudbury,67.204.218.187,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS causes MENTAL RETARDATION,177,75,,194,117,causes,0.589767824619588,906021-FS1-4,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS,RO-has_manifestation
503223397,7/15/2014 15:19:46,,1323619399,7/15/2014 15:19:11,prodege,0.5683,7899370,USA,MI,Bay City,71.13.81.162,no_relation,177,75,,194,117,causes,0.589767824619588,906021-FS1-4,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS,RO-has_manifestation
503223397,7/15/2014 15:48:50,,1323640400,7/15/2014 15:48:37,clixsense,0.6403,7265596,USA,IA,Neola,199.120.116.136,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS causes MENTAL RETARDATION,177,75,,194,117,causes,0.589767824619588,906021-FS1-4,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS,RO-has_manifestation
503223397,7/15/2014 15:52:37,,1323643303,7/15/2014 15:52:09,neodev,0.624,14861092,GBR,I2,Manchester,90.194.137.76,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS causes MENTAL RETARDATION,177,75,,194,117,causes,0.589767824619588,906021-FS1-4,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS,RO-has_manifestation
503223397,7/15/2014 16:25:36,,1323672108,7/15/2014 16:25:18,clixsense,0.475,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,177,75,,194,117,causes,0.589767824619588,906021-FS1-4,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS,RO-has_manifestation
503223397,7/15/2014 16:45:28,,1323695797,7/15/2014 16:45:20,prodege,0.474,2143114,CAN,BC,Vancouver,24.84.160.12,MENTAL RETARDATION causes X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS,177,75,,194,117,causes,0.589767824619588,906021-FS1-4,"Mutations in the L1CAM gene are responsible for four related L1 disorders; X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS as a result of Stenosis of the Aqueduct of Sylvius), MASA (MENTAL RETARDATION Aphasia, Shuffling gait, and Adducted thumbs) syndrome, X linked complicated spastic paraplegia type I (SPG1) and X linked Agenesis of the Corpus Callosum (ACC.",MENTAL RETARDATION,X LINKED HYDROCEPHALUS/HSAS (HYDROCEPHALUS,RO-has_manifestation
503223398,7/15/2014 10:28:54,,1323488494,7/15/2014 10:28:37,clixsense,0.8472,19803139,NLD,06,Veldhoven,212.61.84.196,GABAPENTIN treats PAIN,93,0,,96,10,treats,0.98058067569092,908302-FS1-2,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN,RO-may_treat
503223398,7/15/2014 10:52:01,,1323504529,7/15/2014 10:51:52,clixsense,0.8486,27793793,GBR,C5,Chester,151.230.27.155,GABAPENTIN treats PAIN,93,0,,96,10,treats,0.98058067569092,908302-FS1-2,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN,RO-may_treat
503223398,7/15/2014 12:12:14,,1323551176,7/15/2014 12:11:45,paiddailysurveys,0.6127,11786001,USA,NC,Charlotte,71.28.89.238,GABAPENTIN treats PAIN,93,0,,96,10,treats,0.98058067569092,908302-FS1-2,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN,RO-may_treat
503223398,7/15/2014 13:50:10,,1323586789,7/15/2014 13:49:47,prodege,0.6706,13795372,CAN,NS,Dartmouth,142.68.155.182,GABAPENTIN treats PAIN,93,0,,96,10,treats,0.98058067569092,908302-FS1-2,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN,RO-may_treat
503223398,7/15/2014 13:52:56,,1323587574,7/15/2014 13:51:37,clixsense,0.4333,6334612,USA,OH,Cleveland,108.225.254.58,no_relation,93,0,,96,10,treats,0.98058067569092,908302-FS1-2,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN,RO-may_treat
503223398,7/15/2014 14:27:43,,1323597534,7/15/2014 14:27:23,elite,0.6381,28276268,USA,FL,Boynton Beach,99.114.225.45,GABAPENTIN treats PAIN,93,0,,96,10,treats,0.98058067569092,908302-FS1-2,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN,RO-may_treat
503223398,7/15/2014 14:32:41,,1323599029,7/15/2014 14:32:36,neodev,0.3913,25224036,CAN,ON,Sudbury,67.204.218.187,PAIN treats GABAPENTIN,93,0,,96,10,treats,0.98058067569092,908302-FS1-2,GABAPENTIN was significantly effective in the treatment of pain associated with phantom limb PAIN after amputation and traumatic avulsion of the brachial plexus.,PAIN,GABAPENTIN,RO-may_treat
503223399,7/15/2014 10:23:26,,1323484983,7/15/2014 10:22:52,rewardsspot,0.8889,24482174,GBR,H9,London,46.23.68.180,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA causes ASCITES,107,14,,113,63,causes,0.948683298050514,902717-FS1-4,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA,RO-disease_may_have_finding
503223399,7/15/2014 11:12:06,,1323518848,7/15/2014 11:11:45,elite,0.7417,28397222,GBR,Y4,Usk,31.50.223.75,no_relation,107,14,,113,63,causes,0.948683298050514,902717-FS1-4,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA,RO-disease_may_have_finding
503223399,7/15/2014 14:19:40,,1323595120,7/15/2014 14:19:09,instagc,0.6554,19636746,USA,NY,Andover,192.182.216.225,no_relation,107,14,,113,63,causes,0.948683298050514,902717-FS1-4,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA,RO-disease_may_have_finding
503223399,7/15/2014 14:29:03,,1323597928,7/15/2014 14:28:47,elite,0.6381,28276268,USA,FL,Boynton Beach,99.114.225.45,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA causes ASCITES,107,14,,113,63,causes,0.948683298050514,902717-FS1-4,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA,RO-disease_may_have_finding
503223399,7/15/2014 14:32:29,,1323598971,7/15/2014 14:32:20,neodev,0.3913,25224036,CAN,ON,Sudbury,67.204.218.187,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA causes ASCITES,107,14,,113,63,causes,0.948683298050514,902717-FS1-4,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA,RO-disease_may_have_finding
503223399,7/15/2014 16:51:16,,1323702179,7/15/2014 16:50:51,prodege,0.5758,23541832,USA,AZ,Tempe,149.169.145.144,no_relation,107,14,,113,63,causes,0.948683298050514,902717-FS1-4,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA,RO-disease_may_have_finding
503223399,7/15/2014 16:55:42,,1323706924,7/15/2014 16:55:17,prodege,0.5952,9525153,CAN,ON,Toronto,65.95.187.40,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA causes ASCITES,107,14,,113,63,causes,0.948683298050514,902717-FS1-4,We describe a CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA arising in a 65 year old man who presented ASCITES of unknown origin.,ASCITES,CASE OF DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA,RO-disease_may_have_finding
503223400,7/15/2014 11:20:04,,1323523976,7/15/2014 11:19:39,instagc,0.7264,24252915,GBR,B7,Bristol,77.98.139.82,ANTITUBERCULOSIS treats TB,97,141,,98,157,treats,0.977355554850442,907860-FS1-2,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS,RO-may_treat
503223400,7/15/2014 12:58:38,,1323569171,7/15/2014 12:58:19,elite,0.8028,28503042,USA,NJ,Woodbridge,54.191.150.115,ANTITUBERCULOSIS treats TB,97,141,,98,157,treats,0.977355554850442,907860-FS1-2,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS,RO-may_treat
503223400,7/15/2014 15:48:36,,1323640239,7/15/2014 15:48:14,clixsense,0.6403,7265596,USA,IA,Neola,199.120.116.136,ANTITUBERCULOSIS treats TB,97,141,,98,157,treats,0.977355554850442,907860-FS1-2,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS,RO-may_treat
503223400,7/15/2014 16:25:02,,1323671393,7/15/2014 16:24:48,clixsense,0.475,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,97,141,,98,157,treats,0.977355554850442,907860-FS1-2,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS,RO-may_treat
503223400,7/15/2014 16:50:09,,1323701028,7/15/2014 16:49:28,prodege,0.5758,23541832,USA,AZ,Tempe,149.169.145.144,ANTITUBERCULOSIS treats TB,97,141,,98,157,treats,0.977355554850442,907860-FS1-2,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS,RO-may_treat
503223400,7/15/2014 16:53:39,,1323704718,7/15/2014 16:53:04,prodege,0.5952,9525153,CAN,ON,Toronto,65.95.187.40,ANTITUBERCULOSIS treats TB,97,141,,98,157,treats,0.977355554850442,907860-FS1-2,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS,RO-may_treat
503223400,7/15/2014 16:59:26,,1323711614,7/15/2014 16:59:00,neodev,0.6701,18755947,GBR,H2,Accrington,80.47.185.52,no_relation,97,141,,98,157,treats,0.977355554850442,907860-FS1-2,126  Precautions Related to Treatment of Tuberculosis  Should not be used alone for treatment of TB; must be given in conjunction with other ANTITUBERCULOSIS agents.,TB,ANTITUBERCULOSIS,RO-may_treat
503223401,7/15/2014 10:06:03,,1323474389,7/15/2014 10:05:09,eup_slw,0.9167,20818028,GBR,A7,Birmingham,92.232.139.254,CLOMIPRAMINE treats PANIC DISORDER,64,36,,77,48,treats,0.981980506061966,907891-FS1-2,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE,RO-may_treat
503223401,7/15/2014 10:07:27,,1323475169,7/15/2014 10:06:51,clixsense,0.875,15189335,GBR,E4,Colchester,5.67.141.89,CLOMIPRAMINE treats PANIC DISORDER,64,36,,77,48,treats,0.981980506061966,907891-FS1-2,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE,RO-may_treat
503223401,7/15/2014 10:31:28,,1323490199,7/15/2014 10:31:07,clixsense,0.6875,19162475,GBR,M3,Frome,82.33.126.30,CLOMIPRAMINE treats PANIC DISORDER,64,36,,77,48,treats,0.981980506061966,907891-FS1-2,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE,RO-may_treat
503223401,7/15/2014 11:11:58,,1323518758,7/15/2014 11:11:17,prodege,0.7681,11864493,GBR,Z4,Wrexham,212.219.196.69,no_relation,64,36,,77,48,treats,0.981980506061966,907891-FS1-2,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE,RO-may_treat
503223401,7/15/2014 13:05:16,,1323571746,7/15/2014 13:05:04,clixsense,0.601,20614047,USA,ID,Priest River,174.32.160.124,PANIC DISORDER treats CLOMIPRAMINE,64,36,,77,48,treats,0.981980506061966,907891-FS1-2,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE,RO-may_treat
503223401,7/15/2014 13:49:47,,1323586729,7/15/2014 13:49:18,neodev,0.4671,18339121,USA,SC,Sumter,173.93.188.194,CLOMIPRAMINE treats PANIC DISORDER,64,36,,77,48,treats,0.981980506061966,907891-FS1-2,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE,RO-may_treat
503223401,7/15/2014 16:25:47,,1323672293,7/15/2014 16:25:37,clixsense,0.475,16827630,GBR,A7,Birmingham,86.146.169.103,CLOMIPRAMINE treats PANIC DISORDER,64,36,,77,48,treats,0.981980506061966,907891-FS1-2,"Long term evaluation of paroxetine, CLOMIPRAMINE and placebo in PANIC DISORDER",PANIC DISORDER,CLOMIPRAMINE,RO-may_treat
503223402,7/15/2014 10:29:46,,1323489009,7/15/2014 10:29:10,vivatic,0.8056,25451531,GBR,"","",83.67.28.193,no_relation,298,298,,301,311,causes,0.755928946018454,903983-FS1-4,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY,RO-has_causative_agent
503223402,7/15/2014 10:30:58,,1323489800,7/15/2014 10:30:50,clixsense,0.6875,19162475,GBR,M3,Frome,82.33.126.30,DRUG TOXICITY causes DRUG,298,298,,301,311,causes,0.755928946018454,903983-FS1-4,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY,RO-has_causative_agent
503223402,7/15/2014 11:27:47,,1323528196,7/15/2014 11:27:32,instagc,0.7611,28301350,GBR,K4,Plymouth,92.28.215.248,DRUG causes DRUG TOXICITY,298,298,,301,311,causes,0.755928946018454,903983-FS1-4,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY,RO-has_causative_agent
503223402,7/15/2014 13:51:07,,1323587087,7/15/2014 13:50:45,neodev,0.4671,18339121,USA,SC,Sumter,173.93.188.194,DRUG TOXICITY causes DRUG,298,298,,301,311,causes,0.755928946018454,903983-FS1-4,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY,RO-has_causative_agent
503223402,7/15/2014 14:18:18,,1323594796,7/15/2014 14:17:45,instagc,0.6554,19636746,USA,NY,Andover,192.182.216.225,DRUG causes DRUG TOXICITY,298,298,,301,311,causes,0.755928946018454,903983-FS1-4,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY,RO-has_causative_agent
503223402,7/15/2014 15:20:35,,1323619846,7/15/2014 15:20:09,prodege,0.5683,7899370,USA,MI,Bay City,71.13.81.162,no_relation,298,298,,301,311,causes,0.755928946018454,903983-FS1-4,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY,RO-has_causative_agent
503223402,7/15/2014 15:30:23,,1323626742,7/15/2014 15:30:04,tremorgames,0.5508,24449707,CAN,QC,Laval,96.21.249.72,DRUG causes DRUG TOXICITY,298,298,,301,311,causes,0.755928946018454,903983-FS1-4,"? Tetracycline ? ACE inhibitors ? Angiotensin II antagonists ? DES ? Isotretinoin and other Vitamin A analogues ? Methotrexate ? Thalidomide ? Cyclophosphamide ? Fluoroquinolones ? Misoprostol ? Penicillamine ? Lithium ? Anticonvulsants, especially valproic acid ? Iodides ? Busulfan ? Evidence of DRUG TOXICITY ? Exacerbation of disease for which the DRUG is being used  Data Elements: ? Efficacy assessment.",DRUG,DRUG TOXICITY,RO-has_causative_agent
503223403,7/15/2014 10:50:56,,1323503697,7/15/2014 10:50:40,clixsense,0.8486,27793793,GBR,C5,Chester,151.230.27.155,BOVINE ISOPHANE INSULIN treats TYPE 1 DIABETES,41,100,,55,123,treats,0.992277876713668,908014-FS1-2,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN,RO-may_treat
503223403,7/15/2014 11:12:06,,1323518847,7/15/2014 11:11:45,elite,0.7417,28397222,GBR,Y4,Usk,31.50.223.75,BOVINE ISOPHANE INSULIN treats TYPE 1 DIABETES,41,100,,55,123,treats,0.992277876713668,908014-FS1-2,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN,RO-may_treat
503223403,7/15/2014 11:38:48,,1323534616,7/15/2014 11:38:26,clixsense,0.5726,23233834,GBR,N6,Sunderland,86.17.58.181,BOVINE ISOPHANE INSULIN treats TYPE 1 DIABETES,41,100,,55,123,treats,0.992277876713668,908014-FS1-2,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN,RO-may_treat
503223403,7/15/2014 12:39:22,,1323561559,7/15/2014 12:39:08,instagc,0.7472,18960682,GBR,"","",86.29.147.112,BOVINE ISOPHANE INSULIN treats TYPE 1 DIABETES,41,100,,55,123,treats,0.992277876713668,908014-FS1-2,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN,RO-may_treat
503223403,7/15/2014 14:20:09,,1323595301,7/15/2014 14:19:44,instagc,0.6554,19636746,USA,NY,Andover,192.182.216.225,BOVINE ISOPHANE INSULIN treats TYPE 1 DIABETES,41,100,,55,123,treats,0.992277876713668,908014-FS1-2,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN,RO-may_treat
503223403,7/15/2014 15:53:15,,1323643733,7/15/2014 15:53:01,neodev,0.624,14861092,GBR,I2,Manchester,90.194.137.76,BOVINE ISOPHANE INSULIN treats TYPE 1 DIABETES,41,100,,55,123,treats,0.992277876713668,908014-FS1-2,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN,RO-may_treat
503223403,7/15/2014 16:47:18,,1323697994,7/15/2014 16:47:01,clixsense,0.881,6455807,CAN,BC,Victoria,96.54.172.117,BOVINE ISOPHANE INSULIN treats TYPE 1 DIABETES,41,100,,55,123,treats,0.992277876713668,908014-FS1-2,Thirty two patients with newly diagnosed TYPE 1 DIABETES were treated with the same highly purified BOVINE ISOPHANE INSULIN twice daily for 6 months (Starter group.,TYPE 1 DIABETES,BOVINE ISOPHANE INSULIN,RO-may_treat
503223404,7/15/2014 11:14:18,,1323520250,7/15/2014 11:13:48,prodege,0.7681,11864493,GBR,Z4,Wrexham,212.219.196.69,EPOETIN ALFA treats ANEMIA,106,181,,111,193,treats,0.981980506061966,907996-FS1-2,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA,RO-may_treat
503223404,7/15/2014 11:16:15,,1323521429,7/15/2014 11:15:45,clixsense,0.8306,27871219,NLD,07,Amsterdam,87.210.207.223,EPOETIN ALFA treats ANEMIA,106,181,,111,193,treats,0.981980506061966,907996-FS1-2,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA,RO-may_treat
503223404,7/15/2014 11:28:07,,1323528458,7/15/2014 11:27:48,instagc,0.7611,28301350,GBR,K4,Plymouth,92.28.215.248,EPOETIN ALFA treats ANEMIA,106,181,,111,193,treats,0.981980506061966,907996-FS1-2,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA,RO-may_treat
503223404,7/15/2014 11:28:24,,1323528617,7/15/2014 11:27:55,elite,0.7417,28397222,GBR,Y4,Usk,31.50.223.75,EPOETIN ALFA treats ANEMIA,106,181,,111,193,treats,0.981980506061966,907996-FS1-2,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA,RO-may_treat
503223404,7/15/2014 16:25:36,,1323672109,7/15/2014 16:25:18,clixsense,0.475,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,106,181,,111,193,treats,0.981980506061966,907996-FS1-2,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA,RO-may_treat
503223404,7/15/2014 16:45:38,,1323696046,7/15/2014 16:45:30,prodege,0.474,2143114,CAN,BC,Vancouver,24.84.160.12,EPOETIN ALFA treats ANEMIA,106,181,,111,193,treats,0.981980506061966,907996-FS1-2,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA,RO-may_treat
503223404,7/15/2014 16:47:00,,1323697667,7/15/2014 16:46:14,clixsense,0.881,6455807,CAN,BC,Victoria,96.54.172.117,EPOETIN ALFA treats ANEMIA,106,181,,111,193,treats,0.981980506061966,907996-FS1-2,"Darbepoetin alfa administered at a dose of 3.0 microg/kg every 2 weeks is safe and effective for treating ANEMIA in patients with solid tumors on chemotherapy, and is comparable to EPOETIN ALFA",ANEMIA,EPOETIN ALFA,RO-may_treat
503223405,7/15/2014 10:08:52,,1323475952,7/15/2014 10:08:31,clixsense,0.875,15189335,GBR,E4,Colchester,5.67.141.89,AMANTADINE treats PARKINSON'S DISEASE,23,109,,41,119,treats,0.936329177569044,908349-FS1-2,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE,RO-may_treat
503223405,7/15/2014 10:29:09,,1323488650,7/15/2014 10:28:26,vivatic,0.8056,25451531,GBR,"","",83.67.28.193,AMANTADINE treats PARKINSON'S DISEASE,23,109,,41,119,treats,0.936329177569044,908349-FS1-2,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE,RO-may_treat
503223405,7/15/2014 10:51:17,,1323503996,7/15/2014 10:51:01,rewardsspot,0.6319,17763704,USA,VA,Manassas,198.7.62.204,AMANTADINE treats PARKINSON'S DISEASE,23,109,,41,119,treats,0.936329177569044,908349-FS1-2,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE,RO-may_treat
503223405,7/15/2014 11:15:18,,1323520846,7/15/2014 11:15:03,clixsense,0.8306,27871219,NLD,07,Amsterdam,87.210.207.223,AMANTADINE treats PARKINSON'S DISEASE,23,109,,41,119,treats,0.936329177569044,908349-FS1-2,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE,RO-may_treat
503223405,7/15/2014 13:50:36,,1323586877,7/15/2014 13:49:58,neodev,0.4671,18339121,USA,SC,Sumter,173.93.188.194,PARKINSON'S DISEASE treats AMANTADINE,23,109,,41,119,treats,0.936329177569044,908349-FS1-2,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE,RO-may_treat
503223405,7/15/2014 15:21:11,,1323620301,7/15/2014 15:20:35,prodege,0.5683,7899370,USA,MI,Bay City,71.13.81.162,AMANTADINE treats PARKINSON'S DISEASE,23,109,,41,119,treats,0.936329177569044,908349-FS1-2,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE,RO-may_treat
503223405,7/15/2014 15:30:03,,1323626467,7/15/2014 15:29:43,tremorgames,0.5508,24449707,CAN,QC,Laval,96.21.249.72,AMANTADINE treats PARKINSON'S DISEASE,23,109,,41,119,treats,0.936329177569044,908349-FS1-2,A 61 year old man with PARKINSON'S DISEASE (PD) developed sudden onset visual impairment after initiation of AMANTADINE treatment.,PARKINSON'S DISEASE,AMANTADINE,RO-may_treat
503223406,7/15/2014 10:09:04,,1323476117,7/15/2014 10:08:20,eup_slw,0.9167,20818028,GBR,A7,Birmingham,92.232.139.254,no_relation,19,119,,56,148,causes,0.925820099772551,900203-FS1-4,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS,RO-cause_of
503223406,7/15/2014 11:15:43,,1323521102,7/15/2014 11:15:19,clixsense,0.8306,27871219,NLD,07,Amsterdam,87.210.207.223,no_relation,19,119,,56,148,causes,0.925820099772551,900203-FS1-4,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS,RO-cause_of
503223406,7/15/2014 12:24:45,,1323556091,7/15/2014 12:23:54,paiddailysurveys,0.6127,11786001,USA,NC,Charlotte,71.28.89.238,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS causes SUBSET OF LUPUS ERYTHEMATOSUS,19,119,,56,148,causes,0.925820099772551,900203-FS1-4,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS,RO-cause_of
503223406,7/15/2014 12:27:08,,1323557036,7/15/2014 12:26:29,prodege,0.6058,27934334,GBR,B9,High Wycombe,86.166.72.139,no_relation,19,119,,56,148,causes,0.925820099772551,900203-FS1-4,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS,RO-cause_of
503223406,7/15/2014 13:29:38,,1323580208,7/15/2014 13:28:59,instagc,0.5063,23149109,USA,NC,Cary,24.206.38.18,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS causes SUBSET OF LUPUS ERYTHEMATOSUS,19,119,,56,148,causes,0.925820099772551,900203-FS1-4,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS,RO-cause_of
503223406,7/15/2014 13:47:28,,1323586074,7/15/2014 13:46:56,prodege,0.6706,13795372,CAN,NS,Dartmouth,142.68.155.182,no_relation,19,119,,56,148,causes,0.925820099772551,900203-FS1-4,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS,RO-cause_of
503223406,7/15/2014 15:48:50,,1323640402,7/15/2014 15:48:37,clixsense,0.6403,7265596,USA,IA,Neola,199.120.116.136,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS causes SUBSET OF LUPUS ERYTHEMATOSUS,19,119,,56,148,causes,0.925820099772551,900203-FS1-4,Gilliam recognized SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) as a lupus specific eruption that identifies a unique SUBSET OF LUPUS ERYTHEMATOSUS.,SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS,SUBSET OF LUPUS ERYTHEMATOSUS,RO-cause_of
503223407,7/15/2014 10:09:04,,1323476118,7/15/2014 10:08:20,eup_slw,0.9167,20818028,GBR,A7,Birmingham,92.232.139.254,no_relation,0,88,,16,111,is location of,0.919145030018058,905462-FS1-9,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES,RO-has_finding_site
503223407,7/15/2014 10:25:31,,1323486233,7/15/2014 10:24:56,rewardsspot,0.8889,24482174,GBR,H9,London,46.23.68.180,PERIPHERAL NERVES is location of PERIPHERAL NEUROPATHIES,0,88,,16,111,is location of,0.919145030018058,905462-FS1-9,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES,RO-has_finding_site
503223407,7/15/2014 10:28:25,,1323488195,7/15/2014 10:27:44,vivatic,0.8056,25451531,GBR,"","",83.67.28.193,PERIPHERAL NERVES is location of PERIPHERAL NEUROPATHIES,0,88,,16,111,is location of,0.919145030018058,905462-FS1-9,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES,RO-has_finding_site
503223407,7/15/2014 11:37:24,,1323533712,7/15/2014 11:36:06,clixsense,0.5726,23233834,GBR,N6,Sunderland,86.17.58.181,PERIPHERAL NERVES is location of PERIPHERAL NEUROPATHIES,0,88,,16,111,is location of,0.919145030018058,905462-FS1-9,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES,RO-has_finding_site
503223407,7/15/2014 11:52:04,,1323542592,7/15/2014 11:51:08,instagc,0.4583,21551272,GBR,Q3,Wolverhampton,2.103.57.104,no_relation,0,88,,16,111,is location of,0.919145030018058,905462-FS1-9,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES,RO-has_finding_site
503223407,7/15/2014 12:38:52,,1323561348,7/15/2014 12:38:38,instagc,0.7472,18960682,GBR,"","",86.29.147.112,PERIPHERAL NERVES is location of PERIPHERAL NEUROPATHIES,0,88,,16,111,is location of,0.919145030018058,905462-FS1-9,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES,RO-has_finding_site
503223407,7/15/2014 13:10:04,,1323573540,7/15/2014 13:09:33,neodev,0.4365,28336203,USA,PA,Harrisburg,50.149.53.150,PERIPHERAL NEUROPATHIES is location of PERIPHERAL NERVES,0,88,,16,111,is location of,0.919145030018058,905462-FS1-9,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES,RO-has_finding_site
503223408,7/15/2014 10:19:16,,1323482382,7/15/2014 10:18:52,gifthulk,0.9583,22144176,GBR,U8,Edinburgh,129.215.149.99,no_relation,77,90,,80,99,is location of,0.956182887467515,905057-FS1-9,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA,RO-has_finding_site
503223408,7/15/2014 11:03:32,,1323511603,7/15/2014 11:03:04,prodege,0.6528,28039757,GBR,L8,Southport,109.155.158.54,SKIN is location of URTICARIA,77,90,,80,99,is location of,0.956182887467515,905057-FS1-9,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA,RO-has_finding_site
503223408,7/15/2014 11:20:06,,1323524015,7/15/2014 11:19:46,instagc,0.8431,13763729,USA,"","",75.182.89.225,SKIN is location of URTICARIA,77,90,,80,99,is location of,0.956182887467515,905057-FS1-9,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA,RO-has_finding_site
503223408,7/15/2014 11:26:51,,1323527618,7/15/2014 11:26:32,instagc,0.7611,28301350,GBR,K4,Plymouth,92.28.215.248,SKIN is location of URTICARIA,77,90,,80,99,is location of,0.956182887467515,905057-FS1-9,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA,RO-has_finding_site
503223408,7/15/2014 12:58:38,,1323569172,7/15/2014 12:58:19,elite,0.8028,28503042,USA,NJ,Woodbridge,54.191.150.115,SKIN is location of URTICARIA,77,90,,80,99,is location of,0.956182887467515,905057-FS1-9,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA,RO-has_finding_site
503223408,7/15/2014 14:28:24,,1323597737,7/15/2014 14:28:05,elite,0.6381,28276268,USA,FL,Boynton Beach,99.114.225.45,SKIN is location of URTICARIA,77,90,,80,99,is location of,0.956182887467515,905057-FS1-9,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA,RO-has_finding_site
503223408,7/15/2014 15:30:23,,1323626743,7/15/2014 15:30:04,tremorgames,0.5508,24449707,CAN,QC,Laval,96.21.249.72,SKIN is location of URTICARIA,77,90,,80,99,is location of,0.956182887467515,905057-FS1-9,Repeated exposures over a period of hours induce a state of tolerance in the SKIN so that URTICARIA fails to develop.,SKIN,URTICARIA,RO-has_finding_site
503223409,7/15/2014 10:19:16,,1323482381,7/15/2014 10:18:52,gifthulk,0.9583,22144176,GBR,U8,Edinburgh,129.215.149.99,no_relation,57,146,,71,153,causes,0.629940788348712,908348-FS1-4,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN,RO-may_treat
503223409,7/15/2014 10:22:46,,1323484686,7/15/2014 10:22:17,rewardsspot,0.8889,24482174,GBR,H9,London,46.23.68.180,no_relation,57,146,,71,153,causes,0.629940788348712,908348-FS1-4,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN,RO-may_treat
503223409,7/15/2014 11:27:31,,1323528070,7/15/2014 11:27:07,instagc,0.7611,28301350,GBR,K4,Plymouth,92.28.215.248,no_relation,57,146,,71,153,causes,0.629940788348712,908348-FS1-4,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN,RO-may_treat
503223409,7/15/2014 11:50:29,,1323541420,7/15/2014 11:50:12,neodev,0.6637,21515166,NLD,11,Nootdorp,83.86.58.179,no_relation,57,146,,71,153,causes,0.629940788348712,908348-FS1-4,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN,RO-may_treat
503223409,7/15/2014 12:57:17,,1323568523,7/15/2014 12:56:44,elite,0.8028,28503042,USA,NJ,Woodbridge,54.191.150.115,no_relation,57,146,,71,153,causes,0.629940788348712,908348-FS1-4,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN,RO-may_treat
503223409,7/15/2014 16:54:14,,1323705305,7/15/2014 16:53:40,prodege,0.5952,9525153,CAN,ON,Toronto,65.95.187.40,INSULIN causes TYPE 2 DIABETES,57,146,,71,153,causes,0.629940788348712,908348-FS1-4,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN,RO-may_treat
503223409,7/15/2014 16:58:59,,1323710890,7/15/2014 16:58:45,neodev,0.6701,18755947,GBR,H2,Accrington,80.47.185.52,no_relation,57,146,,71,153,causes,0.629940788348712,908348-FS1-4,"Insulin resistance is a major risk factor for developing TYPE 2 DIABETES caused by the inability of insulin target tissues to respond properly to INSULIN, and contributes to the morbidity of obesity.",TYPE 2 DIABETES,INSULIN,RO-may_treat
503223410,7/15/2014 11:15:49,,1323521147,7/15/2014 11:14:57,prodege,0.6058,27934334,GBR,B9,High Wycombe,86.166.72.139,no_relation,111,75,,158,81,diagnosed by,0.857492925712544,908169-FS1-13,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA,RO-may_treat
503223410,7/15/2014 11:24:26,,1323526347,7/15/2014 11:23:38,prodege,0.7792,15439740,AUS,02,Jannali,27.96.208.89,L DOPA diagnosed by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),111,75,,158,81,diagnosed by,0.857492925712544,908169-FS1-13,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA,RO-may_treat
503223410,7/15/2014 12:36:04,,1323560231,7/15/2014 12:34:54,prodege,0.5236,1852770,USA,TX,Abilene,76.198.102.54,no_relation,111,75,,158,81,diagnosed by,0.857492925712544,908169-FS1-13,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA,RO-may_treat
503223410,7/15/2014 14:28:24,,1323597736,7/15/2014 14:28:05,elite,0.6381,28276268,USA,FL,Boynton Beach,99.114.225.45,L DOPA diagnosed by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),111,75,,158,81,diagnosed by,0.857492925712544,908169-FS1-13,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA,RO-may_treat
503223410,7/15/2014 16:45:28,,1323695795,7/15/2014 16:45:20,prodege,0.474,2143114,CAN,BC,Vancouver,24.84.160.12,L DOPA diagnosed by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),111,75,,158,81,diagnosed by,0.857492925712544,908169-FS1-13,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA,RO-may_treat
503223410,7/15/2014 16:51:51,,1323702855,7/15/2014 16:51:17,prodege,0.5758,23541832,USA,AZ,Tempe,149.169.145.144,no_relation,111,75,,158,81,diagnosed by,0.857492925712544,908169-FS1-13,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA,RO-may_treat
503223410,7/15/2014 16:54:44,,1323705899,7/15/2014 16:54:15,prodege,0.5952,9525153,CAN,ON,Toronto,65.95.187.40,UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) diagnosed by L DOPA,111,75,,158,81,diagnosed by,0.857492925712544,908169-FS1-13,"Clinical efficacy of pramipexole both in monotherapy and combined use with L DOPA were confirmed evaluating by UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) II (Activities of daily living) and III (Motor), in the results of clinical studies mainly performed in USA and European countries and partly in Japan.",UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE),L DOPA,RO-may_treat
503223411,7/15/2014 10:29:24,,1323488763,7/15/2014 10:28:55,clixsense,0.8472,19803139,NLD,06,Veldhoven,212.61.84.196,AHMED GLAUCOMA VALVE treats STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA,50,97,,69,144,treats,0.948683298050514,906368-FS1-2,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA,RO-has_manifestation
503223411,7/15/2014 11:04:44,,1323512623,7/15/2014 11:04:23,prodege,0.6528,28039757,GBR,L8,Southport,109.155.158.54,no_relation,50,97,,69,144,treats,0.948683298050514,906368-FS1-2,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA,RO-has_manifestation
503223411,7/15/2014 13:46:49,,1323585932,7/15/2014 13:46:20,prodege,0.6706,13795372,CAN,NS,Dartmouth,142.68.155.182,no_relation,50,97,,69,144,treats,0.948683298050514,906368-FS1-2,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA,RO-has_manifestation
503223411,7/15/2014 15:19:46,,1323619401,7/15/2014 15:19:11,prodege,0.5683,7899370,USA,MI,Bay City,71.13.81.162,AHMED GLAUCOMA VALVE treats STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA,50,97,,69,144,treats,0.948683298050514,906368-FS1-2,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA,RO-has_manifestation
503223411,7/15/2014 16:45:19,,1323695567,7/15/2014 16:45:05,prodege,0.474,2143114,CAN,BC,Vancouver,24.84.160.12,AHMED GLAUCOMA VALVE treats STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA,50,97,,69,144,treats,0.948683298050514,906368-FS1-2,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA,RO-has_manifestation
503223411,7/15/2014 16:54:44,,1323705903,7/15/2014 16:54:15,prodege,0.5952,9525153,CAN,ON,Toronto,65.95.187.40,AHMED GLAUCOMA VALVE treats STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA,50,97,,69,144,treats,0.948683298050514,906368-FS1-2,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA,RO-has_manifestation
503223411,7/15/2014 16:58:45,,1323710629,7/15/2014 16:58:21,neodev,0.6701,18755947,GBR,H2,Accrington,80.47.185.52,AHMED GLAUCOMA VALVE treats STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA,50,97,,69,144,treats,0.948683298050514,906368-FS1-2,We present our experience with implantation of an AHMED GLAUCOMA VALVE in a 9 year old girl with STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA.,AHMED GLAUCOMA VALVE,STURGE WEBER SYNDROME WITH CHOROIDAL HEMANGIOMA,RO-has_manifestation
503223412,7/15/2014 10:23:26,,1323484982,7/15/2014 10:22:52,rewardsspot,0.8889,24482174,GBR,H9,London,46.23.68.180,ENDSTAGE RENAL FAILURE (ESRD causes ANEMIA OF CHRONIC RENAL FAILURE,42,112,,72,140,causes,0.452267016866645,900181-FS1-4,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD,RO-cause_of
503223412,7/15/2014 11:13:32,,1323519751,7/15/2014 11:12:48,prodege,0.6058,27934334,GBR,B9,High Wycombe,86.166.72.139,no_relation,42,112,,72,140,causes,0.452267016866645,900181-FS1-4,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD,RO-cause_of
503223412,7/15/2014 11:39:44,,1323535084,7/15/2014 11:39:14,clixsense,0.5726,23233834,GBR,N6,Sunderland,86.17.58.181,ANEMIA OF CHRONIC RENAL FAILURE causes ENDSTAGE RENAL FAILURE (ESRD,42,112,,72,140,causes,0.452267016866645,900181-FS1-4,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD,RO-cause_of
503223412,7/15/2014 13:04:37,,1323571510,7/15/2014 13:04:27,clixsense,0.601,20614047,USA,ID,Priest River,174.32.160.124,ENDSTAGE RENAL FAILURE (ESRD causes ANEMIA OF CHRONIC RENAL FAILURE,42,112,,72,140,causes,0.452267016866645,900181-FS1-4,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD,RO-cause_of
503223412,7/15/2014 13:31:01,,1323580607,7/15/2014 13:30:41,instagc,0.5063,23149109,USA,NC,Cary,24.206.38.18,ANEMIA OF CHRONIC RENAL FAILURE causes ENDSTAGE RENAL FAILURE (ESRD,42,112,,72,140,causes,0.452267016866645,900181-FS1-4,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD,RO-cause_of
503223412,7/15/2014 14:12:11,,1323592978,7/15/2014 14:11:34,neodev,0.4365,28336203,USA,PA,Harrisburg,50.149.53.150,ANEMIA OF CHRONIC RENAL FAILURE causes ENDSTAGE RENAL FAILURE (ESRD,42,112,,72,140,causes,0.452267016866645,900181-FS1-4,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD,RO-cause_of
503223412,7/15/2014 14:28:46,,1323597869,7/15/2014 14:28:26,elite,0.6381,28276268,USA,FL,Boynton Beach,99.114.225.45,ANEMIA OF CHRONIC RENAL FAILURE causes ENDSTAGE RENAL FAILURE (ESRD,42,112,,72,140,causes,0.452267016866645,900181-FS1-4,It has been approved for treatment of the ANEMIA OF CHRONIC RENAL FAILURE both in progressive renal failure and ENDSTAGE RENAL FAILURE (ESRD.,ANEMIA OF CHRONIC RENAL FAILURE,ENDSTAGE RENAL FAILURE (ESRD,RO-cause_of
503223413,7/15/2014 10:06:28,,1323474647,7/15/2014 10:06:05,clixsense,0.875,15189335,GBR,E4,Colchester,5.67.141.89,ERGOT ALKALOIDS causes ERGOTISM,334,363,,348,371,causes,0.995893206467704,903773-FS1-4,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM,RO-has_causative_agent
503223413,7/15/2014 10:30:49,,1323489708,7/15/2014 10:30:36,clixsense,0.6875,19162475,GBR,M3,Frome,82.33.126.30,ERGOTISM causes ERGOT ALKALOIDS,334,363,,348,371,causes,0.995893206467704,903773-FS1-4,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM,RO-has_causative_agent
503223413,7/15/2014 11:03:03,,1323511251,7/15/2014 11:02:32,prodege,0.6528,28039757,GBR,L8,Southport,109.155.158.54,ERGOT ALKALOIDS causes ERGOTISM,334,363,,348,371,causes,0.995893206467704,903773-FS1-4,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM,RO-has_causative_agent
503223413,7/15/2014 11:20:52,,1323524364,7/15/2014 11:20:25,instagc,0.8431,13763729,USA,"","",75.182.89.225,ERGOT ALKALOIDS causes ERGOTISM,334,363,,348,371,causes,0.995893206467704,903773-FS1-4,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM,RO-has_causative_agent
503223413,7/15/2014 11:28:24,,1323528616,7/15/2014 11:27:55,elite,0.7417,28397222,GBR,Y4,Usk,31.50.223.75,ERGOT ALKALOIDS causes ERGOTISM,334,363,,348,371,causes,0.995893206467704,903773-FS1-4,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM,RO-has_causative_agent
503223413,7/15/2014 13:05:28,,1323571779,7/15/2014 13:05:20,clixsense,0.601,20614047,USA,ID,Priest River,174.32.160.124,ERGOT ALKALOIDS causes ERGOTISM,334,363,,348,371,causes,0.995893206467704,903773-FS1-4,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM,RO-has_causative_agent
503223413,7/15/2014 16:25:16,,1323671680,7/15/2014 16:25:03,clixsense,0.475,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,334,363,,348,371,causes,0.995893206467704,903773-FS1-4,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ERGOT ALKALOIDS resulting in ERGOTISM) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; hypoglycemia reported [ 1 ] Dosage adjustments not needed; monitor blood glucose concentrations according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",ERGOT ALKALOIDS,ERGOTISM,RO-has_causative_agent
